<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">38314</article-id><article-id pub-id-type="doi">10.7554/eLife.38314</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Stem Cells and Regenerative Medicine</subject></subj-group></article-categories><title-group><article-title>T-ALL leukemia stem cell 'stemness' is epigenetically controlled by the master regulator SPI1</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-123576"><name><surname>Zhu</surname><given-names>Haichuan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-114528"><name><surname>Zhang</surname><given-names>Liuzhen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-114529"><name><surname>Wu</surname><given-names>Yilin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-114530"><name><surname>Dong</surname><given-names>Bingjie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-114531"><name><surname>Guo</surname><given-names>Weilong</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5199-1359</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-114532"><name><surname>Wang</surname><given-names>Mei</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-3292-1413</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-114533"><name><surname>Yang</surname><given-names>Lu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-114534"><name><surname>Fan</surname><given-names>Xiaoying</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-114535"><name><surname>Tang</surname><given-names>Yuliang</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-114536"><name><surname>Liu</surname><given-names>Ningshu</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-123577"><name><surname>Lei</surname><given-names>Xiaoguang</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-112768"><name><surname>Wu</surname><given-names>Hong</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-7545-7919</contrib-id><email>Hongwu@pku.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">The MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences</institution><institution>Peking University</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Peking-Tsinghua Center for Life Sciences</institution><institution>Peking University</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Beijing Advanced Innovation Center for Genomics</institution><institution>Peking University</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Department of Chemical Biology, College of Chemistry and Molecular Engineering</institution><institution>Peking University</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff5"><label>5</label><institution content-type="dept">Drug Discovery Oncology</institution><institution>Bayer Pharmaceuticals</institution><addr-line><named-content content-type="city">Berlin</named-content></addr-line><country>Germany</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Look</surname><given-names>A Thomas</given-names></name><role>Reviewing Editor</role><aff><institution>Harvard Medical School</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Morrison</surname><given-names>Sean J</given-names></name><role>Senior Editor</role><aff><institution>Howard Hughes Medical Institute, University of Texas Southwestern Medical Center</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>09</day><month>11</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>7</volume><elocation-id>e38314</elocation-id><history><date date-type="received" iso-8601-date="2018-05-13"><day>13</day><month>05</month><year>2018</year></date><date date-type="accepted" iso-8601-date="2018-11-09"><day>09</day><month>11</month><year>2018</year></date></history><permissions><copyright-statement>© 2018, Zhu et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Zhu et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-38314-v2.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.38314.001</object-id><p>Leukemia stem cells (LSCs) are regarded as the origins and key therapeutic targets of leukemia, but limited knowledge is available on the key determinants of LSC ‘stemness’. Using single-cell RNA-seq analysis, we identify a master regulator, SPI1, the LSC-specific expression of which determines the molecular signature and activity of LSCs in the murine <italic>Pten</italic>-null T-ALL model. Although initiated by PTEN-controlled β-catenin activation, <italic>Spi1</italic> expression and LSC ‘stemness’ are maintained by a β-catenin-SPI1-HAVCR2 regulatory circuit independent of the leukemogenic driver mutation. Perturbing any component of this circuit either genetically or pharmacologically can prevent LSC formation or eliminate existing LSCs. LSCs lose their ‘stemness’ when <italic>Spi1</italic> expression is silenced by DNA methylation, but <italic>Spi1</italic> expression can be reactivated by 5-AZ treatment. Importantly, similar regulatory mechanisms may be also present in human T-ALL.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>bone marrow</kwd><kwd>thymus</kwd><kwd>human T-ALL cell line</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81602254</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Lu</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>National Key Research</institution></institution-wrap></funding-source><award-id>2017YFA0505200</award-id><principal-award-recipient><name><surname>Lei</surname><given-names>Xiaoguang</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>21472010</award-id><principal-award-recipient><name><surname>Lei</surname><given-names>Xiaoguang</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>21561142002</award-id><principal-award-recipient><name><surname>Lei</surname><given-names>Xiaoguang</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>21625201</award-id><principal-award-recipient><name><surname>Lei</surname><given-names>Xiaoguang</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81570118</award-id><principal-award-recipient><name><surname>Lei</surname><given-names>Xiaoguang</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100011620</institution-id><institution>Center for Life Sciences</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Wu</surname><given-names>Hong</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution>Beijing Advanced Innovation Center for Genomics</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Wu</surname><given-names>Hong</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004326</institution-id><institution>Bayer</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Wu</surname><given-names>Hong</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The identification of key determinants of LSC “stemness” and LSC differentiation that is reversible through an epigenetic mechanism may have considerable implications in understanding leukemia and designing effective therapies.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Acute T cell lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy caused by the accumulation of genetic mutations and altered signaling pathways that affect normal T cell development (<xref ref-type="bibr" rid="bib5">Belver and Ferrando, 2016</xref>; <xref ref-type="bibr" rid="bib17">Ferrando and López-Otín, 2017</xref>; <xref ref-type="bibr" rid="bib18">Girardi et al., 2017</xref>). Current treatment for T-ALL includes high-intensity combination chemotherapies. However, such treatment may cause short- and long-term side effects, and up to 20% of pediatric and 40% of adult T-ALL patients relapse (<xref ref-type="bibr" rid="bib3">Atak et al., 2013</xref>; <xref ref-type="bibr" rid="bib18">Girardi et al., 2017</xref>). Leukemia stem cells (LSCs) are considered to be one of the main causes of drug resistance and therapeutic relapse (<xref ref-type="bibr" rid="bib4">Batlle and Clevers, 2017</xref>; <xref ref-type="bibr" rid="bib6">Blackburn et al., 2014</xref>; <xref ref-type="bibr" rid="bib10">Chiu et al., 2010</xref>; <xref ref-type="bibr" rid="bib65">Visvader, 2011</xref>). Like hematopoietic stem cells, LSCs can self-renew and differentiate into leukemic blast cells (<xref ref-type="bibr" rid="bib7">Bonnet and Dick, 1997</xref>; <xref ref-type="bibr" rid="bib44">Reya et al., 2001</xref>), which makes them ideal candidates for high-efficiency and low-toxicity targeted therapies. However, many questions related to the control mechanisms of LSCs and cancer stem cells (CSCs) in general remain unanswered.</p><p>One question is how CSCs maintain ‘stemness’. Although many driver mutations and dysregulated pathways have been identified in cancers, these are unlikely to be the only mechanisms that maintain CSC ‘stemness’, since the same driver mutations or dysregulated pathways are also present in most cancer cells. One good example is the <italic>Pten</italic>-null T-ALL model that we have generated by the conditional deletion of the <italic>Pten</italic> tumor suppressor gene in fetal liver hematopoietic stem cells (<xref ref-type="bibr" rid="bib19">Guo et al., 2008</xref>). In this model, LSCs are enriched in the Lin<sup>-</sup>CD3<sup>+</sup>KIT<sup>mid</sup> cell subpopulation; these cells are self-renewable and responsible for T-ALL initiation and drug resistance (<xref ref-type="bibr" rid="bib19">Guo et al., 2008</xref>; <xref ref-type="bibr" rid="bib20">Guo et al., 2011</xref>; <xref ref-type="bibr" rid="bib48">Schubbert et al., 2014</xref>). However, since both LSC-enriched and leukemic blast subpopulations share similar genetic alterations, including <italic>Pten</italic> loss and <italic>Tcra/d-Myc</italic> translocation (<xref ref-type="bibr" rid="bib19">Guo et al., 2008</xref>), these driver mutations are unlikely to determine LSC ‘stemness’. Furthermore, treating the <italic>Pten</italic>-null T-ALL model with PI3K inhibitors is effective only before the onset of leukemia, not after leukemia is already underway (<xref ref-type="bibr" rid="bib20">Guo et al., 2011</xref>; <xref ref-type="bibr" rid="bib48">Schubbert et al., 2014</xref>), suggesting that this driver mutation is not responsible for the maintenance of LSC ‘stemness’ once it has been generated.</p><p>A related question is how CSCs lose ‘stemness’ and whether this process is unidirectional or reversible. Such plasticity or reversibility may contribute to some of the conflicting results in the literature regarding the nature and frequency of CSCs (<xref ref-type="bibr" rid="bib4">Batlle and Clevers, 2017</xref>). As small-molecule inhibitors of epigenetic modifiers have been developed and applied to cancer treatments (<xref ref-type="bibr" rid="bib58">Topper et al., 2017</xref>), understanding the nature of CSC maintenance may bear important clinical implications.</p><p>Using the <italic>Pten</italic>-null T-ALL model, we identify a master regulator, SPI1, and a β-catenin-SPI1-HAVCR2 regulatory circuit that are responsible for LSC ‘stemness’ maintenance. This ‘stemness’ maintenance circuit is initiated by the leukemogenic driver mutations, that is, PTEN loss and PI3K-mediated β-catenin activation, but after it is formed, it becomes independent of the driver mutation and the associated PI3K pathway. Furthermore, SPI1’s LSC-specific expression is silenced by DNA methylation, resulting in the loss of LSC ‘stemness’. Our study also provides the fate mapping of leukemia development from LSCs to leukemic blasts at single-cell resolution and identifies potential novel targets for LSC-mediated therapies.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Redefine heterogeneous LSCs at single-cell resolution</title><p>We reported previously that the LSC-enriched Lin<sup>-</sup>CD3<sup>+</sup>KIT<sup>mid</sup> subpopulation in the <italic>Pten</italic>-null T-ALL model contains heterogeneous cells, of which 30% are MYC low, rapamycin- and JQ1 (a BRD4 inhibitor)-resistant, and relatively quiescent in terms of cell cycle (<xref ref-type="bibr" rid="bib19">Guo et al., 2008</xref>; <xref ref-type="bibr" rid="bib48">Schubbert et al., 2014</xref>) (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). To further define this heterogeneous subpopulation, we isolated LSC-enriched and blast subpopulations for RNA-seq analysis (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>, upper panel) and identified one module with a LSC<sup>high</sup>-Blast<sup>0</sup> expression pattern by Weighted Gene Co-expression Network Analysis (WGCNA) (<xref ref-type="bibr" rid="bib68">Zhang and Horvath, 2005</xref>) (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, yellow module). Approximately, 45% of the genes in this module encode membrane proteins such as <italic>Havcr2</italic> (HAVCR2) and <italic>Itgax</italic> (ITGAX) (<xref ref-type="fig" rid="fig1">Figure 1B–C</xref>). Although <italic>Havcr2</italic> and <italic>Itgax</italic> are only expressed in the LSC-enriched subpopulation, the expression levels of these genes vary among different isolates (<xref ref-type="fig" rid="fig1">Figure 1C</xref>), which may reflect the heterogeneity of the LSC-enriched subpopulation. The cell surface expression of HAVCR2 and ITGAX, as measured by FACS analysis, are highly correlated and can further separate the previously identified Lin<sup>-</sup>CD3<sup>+</sup>KIT<sup>mid</sup> LSC-enriched subpopulation into several subgroups (<xref ref-type="fig" rid="fig1">Figure 1D</xref>, upper panel), among which the HAVCR2<sup>high</sup> or HAVCR2<sup>high</sup> ITGAX<sup>high</sup> subgroups are most abundant in the thymus, the critical organ for T cell development and T-ALL initiation (<xref ref-type="bibr" rid="bib19">Guo et al., 2008</xref>;<xref ref-type="bibr" rid="bib20">Guo et al., 2011</xref>) (<xref ref-type="fig" rid="fig1">Figure 1D</xref>, lower panel).</p><fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.38314.002</object-id><label>Figure 1.</label><caption><title>HAVCR2 redefines a heterogeneous LSC-enriched subpopulation at single-cell resolution (<bold>A</bold>) WGCNA analysis for the bulk RNA-seq of LSC-enriched and leukemic blast subpopulations.</title><p>The yellow module contains 220 genes that are preferentially expressed in the LSC-enriched subpopulation (LSC<sup>high</sup>-Blast<sup>0</sup>); (<bold>B</bold>) Gene Ontology (GO) analysis of LSC-enriched genes in the yellow module; (<bold>C</bold>) <italic>Havcr2</italic> and <italic>Itgax</italic> are specifically expressed in LSC-enriched (red) but not in leukemic blast (blue) subpopulations isolated from the indicated hematopoietic organs of M1-M4 <italic>Pten</italic>-null T-ALL mice; (<bold>D</bold>) Upper panel: FACS plots are overlaid to show the differential expression of HAVCR2 and ITGAX in the LSC and blast subpopulations. The previously defined Lin<sup>-</sup>CD3<sup>+</sup>KIT<sup>mid</sup> LSC-enriched subpopulation (in the red box in the left panel) can be further separated into several subgroups based on the expression of the cell-surface markers HAVCR2 and ITGAX. The Lin<sup>-</sup>CD3<sup>+</sup>KIT<sup>-</sup> leukemic blast subpopulation (in the blue box in the left panel) does not express HAVCR2 or ITGAX. Lower panel: Quantitative measurement of the HAVCR2<sup>high</sup>, HAVCR2<sup>mid</sup> and HAVCR2<sup>low</sup> subgroups in different hematopoietic organs from <italic>Pten</italic>-null T-ALL mice (n = 5; *, p&lt;0.05). The HAVCR2<sup>high</sup> subgroup is enriched in the thymus; (<bold>E</bold>) PCA analysis of the single-cell transcriptome shows four subgroups, labeled in different colors. Cells from two independent mice are indicated by different shapes; (<bold>F</bold>) Pseudotime analysis shows the expression profiles of T-ALL cells in 2-D component space. The solid black line shows the main differentiation path from HAVCR2<sup>high</sup> (purple) to blasts (dark green); (<bold>G</bold>) Pseudotemporal ordering of single cells based on <italic>Havcr2</italic> or <italic>Itgax</italic> expression.BM: bone marrow.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-38314-fig1-v2"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.38314.003</object-id><label>Figure 1—figure supplement 1.</label><caption><title>A schematic illustration of procedures used for Bulk and single cell RNAseq analysis.</title><p>(<bold>A</bold>) Heterogenous properties of LSC-enriched and leukemic blast subpopulations. (<bold>B</bold>) Schematic illustrations of the procedures used for the isolation of LSC-enriched and leukemic blast subpopulations and the bulk (upper panel) and single-cell (lower panel) RNA-seq analyses.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-38314-fig1-figsupp1-v2"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.38314.004</object-id><label>Figure 1—figure supplement 2.</label><caption><title>Quality control of single cell RNAseq analysis.</title><p>(<bold>A</bold>) Cell numbers used for single-cell RNA-seq. The numbers in parenthesis represent the number of cells that passed the quality control and were used for further analyses; (<bold>B–C</bold>) Boxplots of the average numbers of transcripts (<bold>B</bold>) and genes (<bold>C</bold>) detected in each subgroup; (<bold>D</bold>) Mapping ratio of the raw reads in each subgroup.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-38314-fig1-figsupp2-v2"/></fig></fig-group><p>To determine whether these heterogeneous groups are organized hierarchically from LSCs to blasts during T-ALL development, we conducted single-cell RNA-seq analysis and identified four subgroups (<xref ref-type="fig" rid="fig1">Figure 1E</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>, lower panel; <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). Pseudotime analysis (<xref ref-type="bibr" rid="bib62">Trapnell et al., 2014</xref>) further indicates that LSCs follow a continuous developmental path towards blasts, progressing from HAVCR2<sup>high</sup> through HAVCR2<sup>mid</sup> and HAVCR2<sup>low</sup> to blasts (<xref ref-type="fig" rid="fig1">Figure 1F</xref>), which can also be visualized by pseudotime analysis of <italic>Havcr2</italic> and <italic>Itgax</italic> expression (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). Collectively, these results confirm the heterogeneity of the previously identified LSC-enriched subpopulation and provide fate mapping of LSC differentiation into blasts at single-cell resolution.</p></sec><sec id="s2-2"><title>The HAVCR2<sup>high</sup> subgroup contains the vast majority of LSC activity</title><p>Single-cell transcriptome analysis indicates that the HAVCR2<sup>high</sup> subgroup is enriched in the hematopoietic stem cell/late progenitor pathways and is relatively quiescent, while the blast subpopulation is enriched in <italic>Myc</italic> lymphoma pathways and active in the cell cycle (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Consistent with this observation, the HAVCR2<sup>high</sup> subgroup also has the lowest c-MYC level among the four subgroups (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), suggesting that the HAVCR2<sup>high</sup> subgroup may contain the MYC<sup>low</sup> cells within the previously defined Lin<sup>-</sup>CD3<sup>+</sup>KIT<sup>mid</sup> LSC-enriched subpopulation (<xref ref-type="bibr" rid="bib19">Guo et al., 2008</xref>; <xref ref-type="bibr" rid="bib48">Schubbert et al., 2014</xref>).</p><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.38314.005</object-id><label>Figure 2.</label><caption><title>Cells in the HAVCR2<sup>high</sup> subgroup are in a quiescent cell cycle state.</title><p>(<bold>A</bold>) Left panel: GSEA analysis shows signaling pathways enriched in the HAVCR2<sup>high</sup> and blast subpopulations. Right panel: Percentage of cells in each phase of the cell cycle based on single-cell RNA-seq; (<bold>B</bold>) Intracellular FACS analyses of MYC levels in the HAVCR2<sup>high</sup>，HAVCR2<sup>mid</sup>, HAVCR2<sup>low</sup> and blast subgroups. Gray line: isotype control.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-38314-fig2-v2"/></fig><p>To determine whether HAVCR2<sup>high</sup> cells are true LSCs, we performed limiting dilution and bone marrow transplantation analyses using 10 to 1000 bone marrow cells from the Lin<sup>-</sup>CD3<sup>+</sup>KIT<sup>mid</sup>, Lin<sup>-</sup>CD3<sup>+</sup>KIT<sup>mid</sup>HAVCR2<sup>high</sup>, and Lin<sup>-</sup>CD3<sup>+</sup>KIT<sup>mid</sup>HAVCR2<sup>low</sup> subgroups (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Cells from the HAVCR2<sup>high</sup> subgroup have the highest leukemia-initiating capacity—nearly every Lin<sup>-</sup>CD3<sup>+</sup>KIT<sup>mid</sup>HAVCR2<sup>high</sup> cell is capable of inducing T-ALL development, compared to 1/14 of the cells in the Lin<sup>-</sup>CD3<sup>+</sup>KIT<sup>mid</sup> subgroup and 1/28 of the cells in the Lin<sup>-</sup>CD3<sup>+</sup>KIT<sup>mid</sup>HAVCR2<sup>low</sup> subgroup (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Consistent with these findings, cells from the HAVCR2<sup>high</sup> subgroup can also induce T-ALL lethality much earlier than cells from the other two subgroups (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Thus, HAVCR2 is a novel surface marker for the isolation of pure LSCs, and the HAVCR2<sup>high</sup> subgroup represents the true LSC population in the <italic>Pten</italic>-null T-ALL model (<xref ref-type="table" rid="table1">Table 1</xref>).</p><table-wrap id="table1" position="float"><object-id pub-id-type="doi">10.7554/eLife.38314.006</object-id><label>Table 1.</label><caption><title>The biological properties of the newly defined HAVCR2<sup>high</sup> LSC subgroup in comparison to other subgroups in the <italic>Pten</italic>-null T-ALL model.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Cell type</th><th valign="top"><break/>HAVCR2<sup>High</sup></th><th valign="top">HAVCR2<sup>mid</sup> and HAVCR2<sup>low</sup></th><th valign="top">Blasts</th></tr></thead><tbody><tr><td valign="top">MYC</td><td valign="top"><named-content content-type="author-callout-style-a3">low</named-content></td><td valign="top"><named-content content-type="author-callout-style-a1">high</named-content></td><td valign="top">high</td></tr><tr><td valign="top">Rapamycin</td><td valign="top"><named-content content-type="author-callout-style-a3">resistance</named-content></td><td valign="top"><named-content content-type="author-callout-style-a1">sensitive</named-content></td><td valign="top">sensitive</td></tr><tr><td valign="top">JQ1</td><td valign="top"><named-content content-type="author-callout-style-a3">resistance</named-content></td><td valign="top"><named-content content-type="author-callout-style-a1">sensitive</named-content></td><td valign="top">sensitive</td></tr><tr><td valign="top">BrdU</td><td valign="top"><named-content content-type="author-callout-style-a3">low</named-content></td><td valign="top"><named-content content-type="author-callout-style-a1">high</named-content></td><td valign="top">high</td></tr><tr><td rowspan="2" valign="top">Surface marker</td><td colspan="2" valign="top">KIT <sup>mid</sup></td><td valign="top">KIT <sup>-</sup></td></tr><tr><td valign="top"><named-content content-type="author-callout-style-a3">HAVCR2<sup>high</sup>/ITGAX<sup>high</sup></named-content> <break/><break/></td><td valign="top"><named-content content-type="author-callout-style-a1"><named-content content-type="author-callout-style-a1">HAVCR2<sup>mid/low</sup>/ITGAX<sup>mid/low</sup></named-content></named-content> <break/></td><td valign="top">HAVCR2<sup>-</sup>/ITGAX<sup>-</sup></td></tr><tr><td valign="top">β-catenin activity</td><td valign="top"><named-content content-type="author-callout-style-a3">high</named-content></td><td valign="top"><named-content content-type="author-callout-style-a1">medium</named-content></td><td valign="top">low</td></tr><tr><td valign="top">LIC activity</td><td valign="top"><named-content content-type="author-callout-style-a3">1/1</named-content></td><td valign="top"><named-content content-type="author-callout-style-a1">1/28</named-content></td><td valign="top">1/10<sup>4</sup>–10<sup>5</sup></td></tr><tr><td valign="top">Pathway</td><td valign="top"><named-content content-type="author-callout-style-a3">Stem/progenitor</named-content></td><td valign="top"/><td valign="top">Myc/lymphoma</td></tr></tbody></table></table-wrap><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.38314.007</object-id><label>Figure 3.</label><caption><title>The HAVCR2<sup>high</sup> subgroup contains the vast majority of LSC activity.</title><p>(<bold>A</bold>) Schematic illustrating the cell isolation, limiting dilution and transplantation procedures used for testing LSC activity as described in Guo et al. (<xref ref-type="bibr" rid="bib19">Guo et al., 2008</xref>); (<bold>B</bold>) LSC frequencies were calculated for each subgroup according to Hu et al. (<xref ref-type="bibr" rid="bib26">Hu and Smyth, 2009</xref>);(<bold>C</bold>) Survival curves showing LSC activity in each of the sorted subgroups upon transplantation (n = 4). Student’s <italic>t</italic>-test was used to calculate the p-value.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-38314-fig3-v2"/></fig></sec><sec id="s2-3"><title>SPI1 is the master regulator of LSC signature genes</title><p>The identification of HAVCR2<sup>high</sup> cells as the true LSC population allows us to define the key determinant for LSC ‘stemness’. We used network component analysis (<xref ref-type="bibr" rid="bib59">Tran et al., 2012</xref>), in which the activity of transcription factors can be deduced based on the expression levels of their target genes. Among the predicted transcription factors (<xref ref-type="bibr" rid="bib35">Liberzon et al., 2011</xref>) that may control the expression of HAVCR2<sup>high</sup> LSC signature genes, SPI1 scores the highest (data not shown). Importantly, approximately 70% of the HAVCR2<sup>high</sup> LSC signature genes overlap with SPI1 target genes identified during T cell development (<xref ref-type="bibr" rid="bib69">Zhang et al., 2012</xref>)(<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Therefore, we decided to focus our subsequent analysis on SPI1.</p><fig-group><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.38314.008</object-id><label>Figure 4.</label><caption><title>SPI1 is the master regulator of LSC signature genes and controls HAVCR2 and c-MYC expression.</title><p>(<bold>A</bold>) Nearly 70% of the genes highly expressed in the HAVCR2<sup>high</sup> subgroup—the LSC signature genes—are potential SPI1 target genes (purple);(<bold>B</bold>) Pseudotemporal ordering of single cells based on <italic>Spi1</italic> or <italic>Myc</italic> expression; (<bold>C</bold>) FACS analysis shows the correlation of HAVCR2 cell surface expression and intracellular SPI1 and c-MYC levels in the LSC-enriched (Lin<sup>-</sup>CD3<sup>+</sup>KIT<sup>mid</sup>; red) and blast (Lin<sup>-</sup>CD3<sup>+</sup>KIT<sup>-</sup>; blue) subpopulations. Gray, isotype control; (<bold>D–E</bold>) ChIP-qPCR analysis identifies SPI1 binding regions in the HAVCR2 promoter (left) and T<italic>cra/d</italic> enhancer A(EA) region (right), using Blast-SPI1 cells; (<bold>F</bold>) ChIP analysis identifies a SPI1 binding site in the endogenous <italic>Myc</italic> enhancer;(<bold>G</bold>) q-PCR shows the fold changes in <italic>Havcr2</italic>, <italic>Itgax</italic>, <italic>Lmo2</italic> and <italic>Myc</italic> expression between Blast-SPI1 cells (red) and Blast-EGFP cells (blue); (<bold>H</bold>) Western blotting shows the SPI1, HAVCR2 and c-Myc protein levels in WT thymus, Blast-EGFP and Blast-SPI1 cells. The fold changes relative to expression in the WT thymus are shown above each lane; (<bold>I</bold>) q-PCR analysis shows the fold changes in <italic>HAVCR2</italic>, <italic>ITGAX</italic>, <italic>LMO2</italic> and <italic>MYC</italic> expression in control shRNA (blue) and shSPI1 knockdown human T-ALL KE-37 cells (red); (<bold>D–I</bold>) All experiments were performed at least three independent times, and the data in D, E, F, G, and I are the means ± S.Ds; *p≤0.05; **p≤0.01; ***p≤0.001.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-38314-fig4-v2"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.38314.009</object-id><label>Figure 4—figure supplement 1.</label><caption><title>A schematic illustration of establishing lines expressing EGFP vector or EGFP-PU.1.</title><p>Upper, a schematic illustration for establishing blast lines expressing the EGFP or EGFP-Spi1 vector; lower, FACS for intracellular SPI1 expression in blast cells infected with the empty EGFP retroviral vector (Blast-EGFP; blue) or the vector with EGFP-Spi1 cDNA (Blast –SPI1; red).</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-38314-fig4-figsupp1-v2"/></fig></fig-group><p>Since the HAVCR2<sup>high</sup> MYC<sup>low</sup> phenotype signifies LSCs, we first examined the correlation of <italic>Spi1</italic>, <italic>Havcr2</italic> and <italic>Myc</italic> expression in HAVCR2<sup>high</sup> and blast cells. The pseudotemporal ordering of the single-cell RNA-seq data and the FACS analyses demonstrate that <italic>Spi1</italic> expression is highest in the HAVCR2<sup>high</sup> subgroup, which is opposite to the differential expression of <italic>Myc</italic> (<xref ref-type="fig" rid="fig4">Figure 4B–C</xref>).</p><p>We further investigated whether SPI1 could transcriptionally regulate <italic>Havcr2</italic> and <italic>Myc</italic> expression by conducting SPI1 ChIP-qPCR analysis on <italic>Spi1-Egfp</italic> stably transformed blasts, using <italic>Egfp</italic>-transfected blasts as a control (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). SPI1 binds strongly to <italic>Havcr2</italic> promoter region 2 (<xref ref-type="bibr" rid="bib70">Zhu et al., 2015</xref>) (<xref ref-type="fig" rid="fig4">Figure 4D</xref>) and the <italic>Tcra</italic> enhancer (EA) region in the translocated <italic>Tcra/d-Myc</italic> allele (<xref ref-type="fig" rid="fig4">Figure 4E</xref>), as well as to the E2 region of the WT allele (<xref ref-type="bibr" rid="bib50">Shi et al., 2013</xref>)(<xref ref-type="fig" rid="fig4">Figure 4F</xref>), suggesting that it may have regulatory effects on both genes. The overexpression of <italic>Spi1</italic> in T-ALL blast cells significantly increases the expression of <italic>Havcr2</italic> and other known SPI1 target genes, such as <italic>Itgax</italic> and <italic>Lmo2</italic> (<xref ref-type="bibr" rid="bib9">Champhekar et al., 2015</xref>; <xref ref-type="bibr" rid="bib63">Turkistany and DeKoter, 2011</xref>; <xref ref-type="bibr" rid="bib66">Yashiro et al., 2017</xref>), but downregulates <italic>Myc</italic> mRNA and protein levels (<xref ref-type="fig" rid="fig4">Figure 4G–H</xref>). In contrast, <italic>SPI1</italic> knockdown in a human T-ALL cell line downregulates the expression of SPI1 target genes but upregulates <italic>MYC</italic> expression (<xref ref-type="fig" rid="fig4">Figure 4I</xref>). Importantly, the positive correlation between <italic>SPI1</italic> and the expression of <italic>HAVCR2</italic> as well as that of SPI1 target genes such as <italic>ITGAX</italic> and <italic>LMO2</italic> can be found in human T-ALL datasets (<xref ref-type="bibr" rid="bib36">Liu et al., 2017</xref>; <xref ref-type="bibr" rid="bib64">Van Vlierberghe et al., 2011</xref>)(<xref ref-type="fig" rid="fig5">Figure 5</xref>), suggesting that the regulation of HAVCR2 expression by SPI1 could play an important role in human T-ALLs.</p><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.38314.010</object-id><label>Figure 5.</label><caption><title><italic>SPI1</italic> expression is positively correlated with <italic>HAVCR2, ITGAX</italic> and <italic>LMO2</italic> expression in human T-ALL.</title><p>Correlation of SPI1 expression with HAVCR2, ITGAX and LMO2 expression in two different cohorts of human T-ALL samples， ρ: Spearman’s rank correlation coefficient, p-value: p-value of Spearman’s rank correlation test.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-38314-fig5-v2"/></fig></sec><sec id="s2-4"><title>SPI1 is essential for LSCs ‘stemness’ and T-ALL development</title><p>SPI1 is an ETS domain-containing transcription factor critical for early T cell progenitor function (<xref ref-type="bibr" rid="bib69">Zhang et al., 2012</xref>), and its overexpression or translocation induces T progenitor cell proliferation and blocks differentiation (<xref ref-type="bibr" rid="bib1">Anderson et al., 2002</xref>; <xref ref-type="bibr" rid="bib49">Seki et al., 2017</xref>), similar to the effects we observed in the <italic>Pten</italic>-null T-ALL model. To functionally determine the role of SPI1 in LSC ‘stemness’ and T-ALL development, we conditionally deleted <italic>Spi1</italic> in the <italic>Pten</italic>-null T-ALL model. Kaplan-Meier survival analysis shows that the lethality caused by T-ALL is delayed proportionally to the numbers of <italic>Spi1</italic> allele that are deleted (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). The tissue architectures of the thymus and spleen appear normal, and no infiltrating leukemia cells can be detected in the liver of the mutant mice (dKO) (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). FACS analyses also show the absence of HAVCR2<sup>high</sup> LSCs and CD3<sup>+</sup> blasts in the thymus, spleen and bone marrow (BM) of the dKO mice (<xref ref-type="fig" rid="fig6">Figure 6C–D</xref>). <italic>Spi1</italic> deletion can also restore spleen weight and organ morphology (<xref ref-type="fig" rid="fig6">Figure 6B</xref>; <xref ref-type="fig" rid="fig6">Figure 6E</xref>). Notably, the lethality seen in the compound homozygotes after 3 months is at least partially due to myeloid abnormalities, a known phenotype associated with SPI1 loss in the myeloid lineage (<xref ref-type="bibr" rid="bib12">Dakic et al., 2007</xref>; <xref ref-type="bibr" rid="bib45">Rosenbauer et al., 2004</xref>; <xref ref-type="bibr" rid="bib53">Steidl et al., 2006</xref>)(data not shown).</p><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.38314.011</object-id><label>Figure 6.</label><caption><title>SPI1 is essential for LSC formation and T-ALL development.</title><p>(<bold>A</bold>) Survival curves for <italic>Cdh5-Cre<sup>+</sup>;Pten<sup>L/L</sup></italic> T-ALL model mice (blue line) with heterozygous (<italic>Cdh5-Cre<sup>+</sup>;Pten<sup>L/L</sup>;Spi1<sup>L/+</sup></italic>; green line) or homozygous (<italic>Cdh5-Cre<sup>+</sup>;Pten<sup>L/L</sup>;Spi1<sup>L/L</sup></italic>; red line) <italic>Spi1</italic> conditional deletion; (<bold>B</bold>) HE-stained images of thymus, spleen and liver tissue from 2-month-old mice with the indicated genotypes;(<bold>C–D</bold>) Comparison of the absolute number of HAVCR2<sup>high</sup> and blast cells in each organ in 2-month-old <italic>Cdh5-Cre<sup>+</sup>;Pten<sup>L/L</sup></italic> (blue bars) and <italic>Cdh5-Cre<sup>+</sup>;Pten<sup>L/L</sup>;Spi11<sup>L/L</sup></italic> (red bars) mice;(<bold>E</bold>) Comparison of spleen weights in the mice in B-C; (<bold>F</bold>) Representative FACS plots show CD3-positive T cells in the thymus of <italic>WT</italic>, <italic>Pten</italic>-null T-ALL and <italic>Pten</italic>/<italic>Spi1</italic> double knockout mice. <italic>WT</italic> and <italic>Pten/Spi1</italic> double knockout mice were 3 months old, and <italic>Pten</italic>-null T-ALL mice were 2 months old. n = 3; (<bold>G</bold>) FACS-Gal analysis of T cell development in the thymus of <italic>Pten/Spi1</italic> double knockout mice. LacZ<sup>+</sup> cells (red dots) and LacZ<sup>−</sup>cells (blue dots) from the same sample are overlaid. C-D, the data are presented as the means ± S.Ds; *p≤0.05; **p≤0.01; ***p≤0. 001.The bars in the HE images and inserts represent 1000 μM and 50 μM, respectively.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-38314-fig6-v2"/></fig><p>To confirm that the absence of T-ALL in dKO mice is not due to a block in T cell development in the <italic>Pten; Spi1</italic>-null T progenitor cells (<xref ref-type="bibr" rid="bib9">Champhekar et al., 2015</xref>; <xref ref-type="bibr" rid="bib52">Spain et al., 1999</xref>), we first quantified CD3<sup>+</sup> T cells in the WT, <italic>Pten</italic>-null and dKO mice and found relatively normal numbers of CD3<sup>+</sup> cells in the dKO thymus (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). We then crossed dKO mice with mice of the <italic>Rosa26<sup>loxp-stop-loxp</sup>-LacZ</italic> reporter line so that LacZ expression could be used to trace the behavior of cells with Cre-mediated deletion of <italic>Pten</italic> and <italic>Spi1</italic> (<xref ref-type="bibr" rid="bib19">Guo et al., 2008</xref>; <xref ref-type="bibr" rid="bib20">Guo et al., 2011</xref>). Our FACS-Gal analysis shows that like LacZ<sup>-</sup> WT cells (blue), LacZ<sup>+</sup> dKO cells (red) in the same animals can undergo differentiation to become CD4<sup>+</sup>CD8<sup>+</sup> double-positive T cells (<xref ref-type="fig" rid="fig6">Figure 6G</xref>). These results suggest that PI3K activation can rescue the T cell developmental block in <italic>Spi1</italic>-null T cell progenitors (<xref ref-type="bibr" rid="bib9">Champhekar et al., 2015</xref>; <xref ref-type="bibr" rid="bib52">Spain et al., 1999</xref>), similar to the findings in our previous report on <italic>Pten;Rag</italic>-null mice (<xref ref-type="bibr" rid="bib20">Guo et al., 2011</xref>).Therefore, SPI1 is essential for <italic>Pten</italic>-null LSC ‘stemness’ and T-ALL development.</p></sec><sec id="s2-5"><title><italic>Spi1</italic> is upregulated at the ETP/DN1 stage during T cell development</title><p>The essential role of SPI1 in regulating LSC signature genes and ‘stemness’ prompted us to investigate how <italic>Spi1</italic> is regulated in the <italic>Pten</italic>-null T-ALL model. During T cell development, <italic>Spi1</italic>, with other T progenitor cell factors and growth factor receptors such as <italic>Bcl11a</italic>, <italic>Lmo2</italic>, <italic>Flt3</italic> and <italic>Kit</italic>, is highly expressed at the early T progenitor (ETP) and double-negative 1 (DN1) stage and is then immediately downregulated during T cell commitment (<xref ref-type="bibr" rid="bib69">Zhang et al., 2012</xref>) (<xref ref-type="fig" rid="fig7">Figure 7A</xref>, upper panel). Interestingly, our pseudotemporal ordering of the single-cell RNA-seq data indicates that the expression patterns of <italic>Spi1</italic> and these factors and receptors are largely unchanged in the <italic>Pten</italic>-null T-ALL model compared to normal T cell development (<xref ref-type="fig" rid="fig7">Figure 7A</xref>, lower panels). Furthermore, these factors and receptors are highly expressed in the HAVCR2<sup>high</sup> subgroup and downregulated in the HAVCR2<sup>mid</sup> and HAVCR2<sup>low</sup> subgroups, suggesting that HAVCR2<sup>high</sup>SPI1<sup>high</sup> LSCs may be generated at the ETP/DN1 stage (<xref ref-type="fig" rid="fig7">Figure 7A</xref>, low panels). Indeed, when we crossed <italic>Spi1-GFP</italic> reporter mice (<xref ref-type="bibr" rid="bib39">Nutt et al., 2005</xref>) to <italic>Pten</italic>-null T-ALL model mice, we found that <italic>Spi1-GFP</italic> expression is significantly upregulated at the ETP/DN1 stage (<xref ref-type="fig" rid="fig7">Figure 7B</xref>).</p><fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.38314.012</object-id><label>Figure 7.</label><caption><title><italic>Spi1</italic> is upregulated at the ETP/DN1 stage during T cell development.</title><p>(<bold>A</bold>) Upper panel: Diagram of progenitor cell factors and growth factor receptors involved in early T cell development, modified from (<xref ref-type="bibr" rid="bib47">Rothenberg et al., 2016</xref>); lower panels: pseudotemporal ordering of single cells based on <italic>Spi1</italic>, <italic>Bcl11a</italic>, <italic>Lmo2</italic>, <italic>Flt3</italic> and <italic>Kit</italic> expression; (<bold>B</bold>) <italic>Spi1-GFP</italic> expression is upregulated in ETP/DN1progenitor cells from <italic>Cdh5-Cre<sup>+</sup>;Pten<sup>L/L</sup>;Spi1<sup>GFP/+</sup>Pten</italic> null (red line), compared to that in <italic>Cdh5-Cre<sup>-</sup>;Pten<sup>+/L</sup>;Spi1<sup>+/+</sup></italic> WT (gray line), <italic>Cdh5-Cre<sup>+</sup>;Pten<sup>+/L</sup>;Spi1<sup>GFP/+</sup>Pten</italic> heterozygous (purple line) and <italic>Cdh5-Cre<sup>-</sup>;Pten<sup>+/L</sup>;Spi1<sup>GFP/+</sup></italic> WT GFP<sup>+</sup> (green line) mice.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-38314-fig7-v2"/></fig></sec><sec id="s2-6"><title>A β-catenin-SPI1-HAVCR2 regulatory circuit is required for <italic>Spi1</italic> upregulation and LSC ‘stemness’</title><p><italic>β</italic>-Catenin is an important transcription factor regulating <italic>Spi1</italic> expression in the T cell lineage (<xref ref-type="bibr" rid="bib46">Rosenbauer et al., 2006</xref>). Previous works by us and others suggest that <italic>β</italic>−catenin is critical for LSC self-renewal (<xref ref-type="bibr" rid="bib19">Guo et al., 2008</xref>) and RAG-dependent aberrant TCR rearrangement (<xref ref-type="bibr" rid="bib14">Dose et al., 2014</xref>; <xref ref-type="bibr" rid="bib20">Guo et al., 2011</xref>), a mechanism underlying the reoccurring <italic>Tcra/d -Myc</italic> translocation caused by PTEN loss or <italic>β</italic>−catenin activation observed in T-ALLs (<xref ref-type="bibr" rid="bib19">Guo et al., 2008</xref> <xref ref-type="bibr" rid="bib27">Kaveri et al., 2013</xref>). Indeed, the overexpression of <italic>β</italic>-catenin in a human T-ALL cell line leads to the significantly increased expression of <italic>SPI1</italic> from its endogenous promoter and subsequently promotes the expression of its target gene <italic>HAVCR2</italic> but downregulates <italic>MYC</italic> expression (<xref ref-type="fig" rid="fig8">Figure 8A</xref>).</p><fig id="fig8" position="float"><object-id pub-id-type="doi">10.7554/eLife.38314.013</object-id><label>Figure 8.</label><caption><title><italic>Spi1</italic> expression is maintained by <italic>β</italic>-catenin-SPI1-HAVCR2 regulatory circuit.</title><p>(<bold>A</bold>) q-PCR analysis of SPI1 and SPI1-regulated HAVCR2 and c-MYC expressions after the overexpression of active β-catenin in the Jurkat T-ALL cell line (red bars). The data are normalized to that of empty plasmid controls (blue bars); (<bold>B–E</bold>) Upper panels: quantitative intracellular FACS analyses of P-GSK-3β, non-phospho-β-catenin, P-p65 and SPI1 levels in the HAVCR2<sup>high</sup>, HAVCR2<sup>low</sup> and blast subgroups; lower panels: representative intracellular FACS analysis of P-GSK-3β, non-phospho-β-catenin, P-p65 and SPI1 levels in the HAVCR2<sup>high</sup>, HAVCR2<sup>low</sup> and blast subgroups. Gray line, isotype control;(<bold>F</bold>) FACS analysis shows cells in the HAVCR2<sup>high</sup> subgroup at the ETP/DN1 stage, which are absent in WT and <italic>dKO</italic> mice; (<bold>G</bold>) Representative FACS plots show the number of cells in the HAVCR2<sup>high</sup> subgroup in the different drug treatment groups. The data in A, B, C, D and E are the means ± S.Ds of 3 independent tests; *p≤0.05; **p≤0.01; ***p≤0.001.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-38314-fig8-v2"/></fig><p>PTEN loss or PI3K/AKT activation is known to activate <italic>β</italic>−catenin by phosphorylating GSK-3β and preventing GSK-3β-mediated <italic>β</italic>−catenin degradation (<xref ref-type="bibr" rid="bib13">Dan et al., 2008</xref>; <xref ref-type="bibr" rid="bib31">Kikushige et al., 2015</xref>; <xref ref-type="bibr" rid="bib41">Persad et al., 2001</xref>). Although the HAVCR2<sup>high</sup>, HAVCR2<sup>low</sup> and blast subgroups have similar levels of P-GSK-3β due to PTEN loss (<xref ref-type="fig" rid="fig8">Figure 8B</xref>, upper and lower panels), the HAVCR2<sup>high</sup> subgroup has a much higher level of non-phospho-<italic>β</italic>−catenin (the active form of <italic>β</italic>−catenin) and SPI1 than HAVCR2<sup>low</sup> and blast subgroups <italic>in vivo</italic> (<xref ref-type="fig" rid="fig8">Figure 8C and E</xref>, upper and lower panels), suggesting that SPI1-mediated LSC formation may depend on mechanisms other than the oncogenic driver mutation PTEN loss.</p><p>HAVCR2 signaling can activate NFκB and <italic>β</italic>−catenin and promote AML LSC formation and self-renewal (<xref ref-type="bibr" rid="bib31">Kikushige et al., 2015</xref>). Since we identified HAVCR2 as the SPI1 target gene, we hypothesized that HAVCR2 signaling may in turn activate <italic>Spi1</italic> expression and promote T-ALL LSC formation. Intracellular FACS analyses show that among the four subgroups, the HAVCR2<sup>high</sup> subgroup, which has the highest <italic>Spi1</italic> expression, also has the highest level of both phospho-p65 and non-phospho-<italic>β</italic>−catenin (<xref ref-type="fig" rid="fig8">Figure 8D–E</xref>, upper and lower panels), indicating that HAVCR2 signaling must play an important role in the hyperactivation of NFκB and <italic>β</italic>−catenin. Consistent with this hypothesis, the genetic deletion of <italic>Spi1</italic> can prevent both HAVCR2<sup>high</sup> LSC formation at the ETP/DN1 stage and T-ALL development (<xref ref-type="fig" rid="fig8">Figure 8F</xref>). The pharmacological inhibition of <italic>β</italic>−catenin activation by the novel tankyrase inhibitor BAY6060, but not the inhibition of PI3K activity by BAY1082439 alone (<xref ref-type="bibr" rid="bib25">Hill et al., 2017</xref>), can also significantly reduce the number of HAVCR2<sup>high</sup> LSCs <italic>in vivo</italic> in late-stage T-ALL (<xref ref-type="fig" rid="fig8">Figure 8G</xref>). Together, these results suggest that although <italic>Spi1</italic> upregulation is initiated by PTEN loss, SPI1-mediated LSC formation and ‘stemness’ are maintained by the <italic>β</italic>−catenin–SPI1-HAVCR2 regulatory circuit.</p></sec><sec id="s2-7"><title>LSCs loses their ‘stemness’ when <italic>Spi1</italic> expression is silenced by DNA methylation</title><p>How cancer stem cells lose ‘stemness’ and whether this process is unidirectional or reversible are currently unknown. Since <italic>Spi1</italic> expression is drastically reduced from the HAVCR2<sup>high</sup> stage to the HAVCR2<sup>low</sup> stage (<xref ref-type="fig" rid="fig7">Figure 7A</xref>, lower panel), we hypothesized that a <italic>Spi1</italic> silencing mechanism may explain the loss of LSC ‘stemness’ during differentiation. DNA methylation is one of the major epigenetic mechanisms in regulating gene expression during normal development. Although the global methylation patterns across the LSC signature and blast signature genes are similar (<xref ref-type="fig" rid="fig9">Figure 9A–B</xref>), the <italic>Spi1</italic> promoter is significantly hypomethylated in LSCs compared to blasts and normal T cell controls (<xref ref-type="fig" rid="fig9">Figure 9C</xref>). Consistently, the 4 CpG islands on the <italic>Spi1</italic> promoter (<xref ref-type="bibr" rid="bib16">Fernández-Nestosa et al., 2013</xref>) are not methylated in the HAVCR2<sup>high</sup> subgroup but gradually become methylated in the HAVCR2<sup>mid</sup> and HAVCR2<sup>low</sup> subgroups and are completely methylated in blasts (<xref ref-type="fig" rid="fig9">Figure 9D</xref>), which may explain the trend in <italic>Spi1</italic> expression and <italic>Spi1</italic>-controlled <italic>Havcr2</italic> and <italic>Itgax</italic> expression (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, upper panel; <xref ref-type="fig" rid="fig1">Figure 1G</xref>). Conversely, treating leukemic blasts with the DNMT inhibitor 5-AZ can increase the expression of <italic>Spi1</italic> and its regulated LSC signature genes <italic>in vitro</italic> (<xref ref-type="fig" rid="fig9">Figure 9E</xref>) and induces the SPI1<sup>+</sup> and MYC<sup>low</sup> subgroups <italic>in vivo</italic> (<xref ref-type="fig" rid="fig9">Figure 9F</xref>), demonstrating that <italic>Spi1</italic> expression is reversibly regulated by DNA methylation, which in turn regulates LSC signature gene expression.</p><fig id="fig9" position="float"><object-id pub-id-type="doi">10.7554/eLife.38314.014</object-id><label>Figure 9.</label><caption><title><italic>Spi1</italic> expression is controlled by DNA methylation</title><p>(<bold>A</bold>) Schematic illustrating the procedures involved in cell isolation and RRBS analysis; (<bold>B</bold>) DNA methylation status of genes specifically expressed in the leukemic blast (left) and LSC-enriched (right) subpopulations; (<bold>C</bold>) <italic>Spi1</italic> promoter methylation status in normal T cells, LSC-enriched cells and blast-enriched cells.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-38314-fig9-v2"/></fig><p>To test the relevance of our findings to human T-ALL, we used two human T-ALL cell lines, KE-37 and CEM (<xref ref-type="bibr" rid="bib8">Burger et al., 1999</xref>; <xref ref-type="bibr" rid="bib57">Tatetsu et al., 2007</xref>). KE-37 expresses <italic>SPI1</italic> and <italic>HAVCR2</italic>, while CEM does not (<xref ref-type="fig" rid="fig10">Figure 10A</xref>), consistent with the methylation status of the <italic>SPI1</italic> promoter (<xref ref-type="fig" rid="fig10">Figure 10B</xref>). 5-AZ treatment can upregulate the expression of <italic>SPI1</italic> and its target <italic>HAVCR2</italic> but downregulate <italic>c-MYC</italic> expression in CEM cells, similar to the effects of our blast treatment, while no change can be detected in KE-37 cells (<xref ref-type="fig" rid="fig10">Figure 10C</xref>), demonstrating that <italic>SPI1</italic> expression is also regulated by DNA methylation in human T-ALL. To test whether the leukemogenic activity could be modulated by <italic>SPI1</italic> expression in human T-ALL cell lines, we injected placebo- or 5-AZ-treated CEM cells and monitored the T-ALL development induced by these cells <italic>in vivo</italic>. 5-AZ treatment significantly accelerated T-ALL development (<xref ref-type="fig" rid="fig10">Figure 10D</xref>). However, cell lines are not the best model system for studying LSC activity, and the essential role of SPI1 in regulating LSC activity in human T-ALL needs to be determined using patient samples and PDX models.</p><fig id="fig10" position="float"><object-id pub-id-type="doi">10.7554/eLife.38314.015</object-id><label>Figure 10.</label><caption><title>Human <italic>SPI1</italic> expression is silenced by DNA methylation</title><p>(<bold>A</bold>) FACS analysis shows the surface expression of HAVCR2 and the intracellular level of SPI1 in the human T-ALL cell lines KE-37 and CEM.(<bold>B</bold>) Methylation status of CpG islands in the <italic>SPI1</italic> promoter in the human T-ALL cell lines KE-37 and CEM; (<bold>C</bold>) q-PCR analysis of <italic>SPI1</italic>, <italic>HAVCR2</italic> and <italic>Myc</italic> expression in KE-37 and CEM cells without (blue) and with(pink and red) 5-AZ treatment <italic>in vitro</italic>; (<bold>D</bold>) Survival curves show T-ALL development by CEM cells without (blue) and with (red) 5-AZ treatment upon transplantation (n = 4; <italic>t</italic>-test). The data in Care the means ± S.Ds of 3 independent tests; *p≤0.05; **p≤0.01; ***p≤0.001.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-38314-fig10-v2"/></fig></sec><sec id="s2-8"><title>Cotargeting oncogenic driver mutations and LSC ‘stemness’ maintenance circuit</title><p>We previously reported that treating <italic>Pten</italic>-null T-ALL model mice with a PI3K inhibitor is effective only at the preleukemia stage, not after leukemia has developed (<xref ref-type="bibr" rid="bib20">Guo et al., 2011</xref>; <xref ref-type="bibr" rid="bib6">Blackburn et al., 2014</xref>), suggesting the importance of cotargeting the LSC ‘stemness’ maintenance pathway once LSCs have been generated. Since SPI1 is essential for LSC formation and <italic>SPI1</italic> expression is regulated and maintained by the β-catenin-SPI1-HAVCR2 regulatory circuit, we hypothesized that cotargeting any component of this circuit with an anti-PI3K inhibitor may effectively eliminate existing T-ALL cells.</p><p>To test this hypothesis, we first treated age-matched leukemia-stage <italic>Pten</italic>-null T-ALL mice with DB1976 (<xref ref-type="fig" rid="fig11s1">Figure 11—figure supplement 1A–B</xref>), a compound known to specifically disrupt the interactions between SPI1 and its targets (<xref ref-type="bibr" rid="bib2">Antony-Debré et al., 2017</xref>; <xref ref-type="bibr" rid="bib38">Munde et al., 2014</xref>; <xref ref-type="bibr" rid="bib54">Stephens et al., 2016</xref>). DB1976 can significantly inhibit the expression of <italic>Havcr2</italic> and other SPI1 target genes <italic>in vitro</italic> (<xref ref-type="fig" rid="fig11">Figure 11A</xref>) and reduce the number of HAVCR2<sup>high</sup> LSCs <italic>in vivo</italic> (<xref ref-type="fig" rid="fig11">Figure 11B</xref>, left panel), confirming that SPI1 is not only important for LSC formation but also for LSC maintenance. However, only when combined with a debulking anti-PI3K agent such as rapamycin (<xref ref-type="bibr" rid="bib19">Guo et al., 2008</xref>) could DB1976 significantly reduce the leukemia burden, as demonstrated by the nearly complete absence of leukemic blasts in the hematopoietic organs (<xref ref-type="fig" rid="fig11">Figure 11B</xref>, right panel). Consequently, combination treatment can markedly prolong the animal lifespan (<xref ref-type="fig" rid="fig11">Figure 11C</xref>), restore the spleen weight and morphology, and eliminate infiltrating leukemic cells in the lung, kidney and liver without a significant change in animal body weight (<xref ref-type="fig" rid="fig11">Figure 11D–E</xref>; <xref ref-type="fig" rid="fig11s1">Figure 11—figure supplement 1C</xref>). Similar results were obtained when we replaced DB1976 and rapamycin with BAY6060 and BAY1082439, respectively (<xref ref-type="fig" rid="fig11">Figure 11D–E</xref>; <xref ref-type="fig" rid="fig11s1">Figure 11—figure supplement 1D</xref>). BAY1082439 can inhibit PI3Kδ, which is essential for <italic>Pten-null</italic> leukemia (<xref ref-type="bibr" rid="bib55">Subramaniam et al., 2012</xref>), at nanomolar concentrations (<xref ref-type="bibr" rid="bib2">Antony-Debré et al., 2017</xref>). The inhibition of tankyrase by BAY6060 can significantly reduce <italic>β</italic>-catenin activity and consequently decrease <italic>Spi1</italic> expression and the number of HAVCR2<sup>high</sup> LSCs <italic>in vivo</italic> (<xref ref-type="fig" rid="fig12">Figure 12A</xref>). In combination, BAY6060 and BAY1082439 could significantly prolong the animal lifespan and almost completely eliminate LSCs and blasts (<xref ref-type="fig" rid="fig12">Figure 12B</xref>, <xref ref-type="fig" rid="fig11">Figure 11E</xref> and <xref ref-type="fig" rid="fig8">Figure 8G</xref>).</p><fig-group><fig id="fig11" position="float"><object-id pub-id-type="doi">10.7554/eLife.38314.016</object-id><label>Figure 11.</label><caption><title>Cotargeting oncogenic driver mutations and the LSC ‘stemness’ maintenance circuit eliminated LSC and T-ALL cells</title><p>(<bold>A</bold>) q-PCR analysis of <italic>Spi1</italic> and <italic>Spi1</italic>-regulated <italic>Havcr2</italic>, <italic>Itgax</italic> and <italic>Lmo2</italic> expression after 24 hr of DB1976 treatment (blue bars). The data are normalized to that of the untreated controls (red bars); (<bold>B</bold>) A comparison of the absolute number of HAVCR2<sup>high</sup> and blast cells in the untreated (gray bars) and differently treated groups; (<bold>C</bold>) Survival curve of <italic>Cdh5-Cre<sup>+</sup>;Pten<sup>L/L</sup></italic> model mice treated with DB1976 and rapamycin alone and in combination; (<bold>D</bold>) A comparison of the spleen weights of 2-month-old WT mice, untreated <italic>Cdh5-Cre<sup>+</sup>;Pten<sup>L/L</sup></italic> mice, and combination-treated mice upon euthanasia; (<bold>E</bold>) HE-stained images of spleen, lung, kidney and liver tissue from2-month-old WT, untreated and combination-treated mice. A, B and D: the data are presented as the means ± S.Ds; ***p≤0.001; the bars in the HE images and inserts represent 1000 μM and 50 μM, respectively.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-38314-fig11-v2"/></fig><fig id="fig11s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.38314.017</object-id><label>Figure 11—figure supplement 1.</label><caption><title>A schematic illustration of dosing schedules and treatment cohorts.</title><p>(<bold>A</bold>) Table showing all inhibitors used in this study, including their targets, <italic>in vivo</italic> dosages and references. (<bold>B</bold>) Schematic illustration of the different treatment cohorts and analyses; (<bold>C– E</bold>) Lack of general body weight loss in each treatment cohort.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-38314-fig11-figsupp1-v2"/></fig></fig-group><fig id="fig12" position="float"><object-id pub-id-type="doi">10.7554/eLife.38314.018</object-id><label>Figure 12.</label><caption><title>Cotargeting oncogenic driver mutations and LSC ‘stemness’ maintenance circuit.</title><p>(<bold>A</bold>) Comparison of the HAVCR2<sup>high</sup> subgroup population (left panel) and of the levels of non-phosphorylated <italic>β</italic>-catenin (middle panel) and SPI1 (right panel) within the HAVCR2<sup>high</sup> subgroup without (upper panels) and with BAY6060 treatment (low panels); (<bold>B</bold>) Survival curve for <italic>Cdh5-Cre<sup>+</sup>;Pten<sup>L/L</sup></italic> mice treated with BAY6060 and BAY1082439 alone and in combination; (<bold>C</bold>) Survival curve for <italic>Cdh5-Cre<sup>+</sup>;Pten<sup>L/L</sup></italic> mice treated with rapamycin in combination with either an IgG control antibody or an anti-HAVCR2 antibody.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-38314-fig12-v2"/></fig><p>Compared with β-catenin and SPI1, HAVCR2 may be a better therapeutic target as it is normally not expressed in hematopoietic stem and progenitor cells (<xref ref-type="bibr" rid="bib29">Kikushige et al., 2010</xref>), and inhibition of HAVCR2 would therefore be less toxic. An anti-HAVCR2 antibody has been used clinically in immunotherapy and in targeting AML LSCs (<xref ref-type="bibr" rid="bib29">Kikushige et al., 2010</xref>; <xref ref-type="bibr" rid="bib32">Koyama et al., 2016</xref>). When combined with rapamycin, the anti-HAVCR2 antibody showed a therapeutic effect similar to that seen for DB1976/rapamycin and BAY6060/BAY1082439 combinations (<xref ref-type="fig" rid="fig11">Figure 11D–E</xref> and <xref ref-type="fig" rid="fig12">Figure 12C</xref>; <xref ref-type="fig" rid="fig11s1">Figure 11—figure supplement 1E</xref>). Together, these results suggest that inhibiting any component in the β-catenin-SPI1-HAVCR2 regulatory circuit will inhibit LSC ‘stemness’ maintenance and lead to the effective elimination of HAVCR2-positive T-ALL cells in the presence of an effective debulking agent targeting the PI3K pathway, such as rapamycin or BAY1082439.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Our study suggests that two layers of control mechanisms may play essential roles in leukemogenesis (<xref ref-type="fig" rid="fig13">Figure 13</xref>). The first layer is driven by the loss of the PTEN tumor suppressor or the activation of the PI3K pathway, which leads to β-catenin activation, <italic>Tcra/d-Myc</italic> translocation and T-ALL development. The second layer is controlled by the master regulator SPI1, which determines LSC signature gene expression and maintains LSC ‘stemness’ (<xref ref-type="fig" rid="fig4">Figures 4</xref>–<xref ref-type="fig" rid="fig6">6</xref>). SPI1 upregulation is initiated by PI3K-controlled <italic>β</italic>-catenin activation,while the LSC-specific expression of SPI1 is reinforced by the <italic>β</italic>-catenin-SPI1-HAVCR2 regulatory circuit (<xref ref-type="fig" rid="fig8">Figure 8</xref>). Once formed, LSCs are very sensitive to any perturbation of this regulatory circuit but are less dependent on the PI3K pathway, as inhibiting the PI3K pathway at the leukemia stage has little effect on the LSC number (<xref ref-type="fig" rid="fig11">Figures 11</xref>–<xref ref-type="fig" rid="fig12">12</xref>)(<xref ref-type="bibr" rid="bib19">Guo et al., 2008</xref>; <xref ref-type="bibr" rid="bib6">Blackburn et al., 2014</xref>). SPI1 is silenced by DNA methylation, which leads to the downregulated expression of LSC signature genes, the loss of LSC ‘stemness’ and leukemic differentiation (<xref ref-type="fig" rid="fig9">Figures 9</xref>–<xref ref-type="fig" rid="fig10">10</xref>). Although the PTEN loss and <italic>Tcra/d-Myc</italic> translocation in the first layer of the leukemogenesis mechanism are hardwired and present in both LSCs and leukemia blasts, the SPI1 expression and maintenance in the second layer of the LSC ‘stemness’ mechanism is reversible and present only in LSCs (<xref ref-type="fig" rid="fig13">Figure 13</xref>). Similar two-layer control mechanisms may also be present in other types of cancer in which CSCs are known to play essential roles.</p><fig id="fig13" position="float"><object-id pub-id-type="doi">10.7554/eLife.38314.019</object-id><label>Figure 13.</label><caption><title>Two-layer control mechanisms for leukemogenesis and LSC maintenance.</title></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-38314-fig13-v2"/></fig><p>This two-layer model may have important implications for LSC-targeted therapies. First, targeting driver mutations or dysregulated pathways in the first layer may be sufficient for debulking the leukemia mass but not for eliminating LSCs unless the mechanism for maintaining LSC ‘stemness’ is simultaneously inhibited (<xref ref-type="fig" rid="fig11">Figures 11</xref>–<xref ref-type="fig" rid="fig12">12</xref>). Second, since the expression of the LSC master regulator SPI1 can be reversibly regulated by epigenetic mechanisms (<xref ref-type="fig" rid="fig9">Figures 9</xref>–<xref ref-type="fig" rid="fig10">10</xref>), this model would predict poorer outcomes if leukemia controlled by such a mechanism was treated with 5-AZ or similar agents and would suggest that the reactivation of SPI1 expression could be a potential mechanism for LSC-mediated therapeutic resistance.</p><p>A broad spectrum of epigenetic and genetic alterations has been found in virtually all cancer types. In certain cases, mutations within the epigenetic control machinery can influence global gene expression and cause subsequent cancer heterogeneity and clonal diversity; in other cases, epigenetic mechanisms may act on a specific transcription factor. Although we did not detect significant global methylation differences between LSC signature genes and blast signature genes, SPI1, the master regulator found in this study, is specifically methylated during differentiation from the HAVCR2<sup>high</sup> to the HAVCR2<sup>low</sup> phenotype (<xref ref-type="fig" rid="fig9">Figure 9</xref>), resulting in down regulating the expression of LSC signature genes. The mechanism that controls the specific methylation of SPI1 is currently unknown, but we predict that a similar mechanism may also regulate SPI1 silencing during T cell commitment (<xref ref-type="bibr" rid="bib69">Zhang et al., 2012</xref>). The alteration of this silencing mechanism may lead to a block of T cell development and contribute to early progenitor type of T-ALL, such as ETP-T-ALL.</p><p>The identification of specific markers expressed only in LSCs is essential for isolating pure LSCs and studying their control mechanisms. Using an advanced single-cell sequencing technique, we identified HAVCR2 as an LSC-specific biomarker that can be used to isolate ‘pure’ LSCs, as determined by our limiting dilution and transplantation experiments (<xref ref-type="fig" rid="fig1">Figures 1</xref>–<xref ref-type="fig" rid="fig3">3</xref>). Most of the cell surface markers currently used to isolate LSCs or CSCs are irrelevant to the function of LSCs or CSCs. HAVCR2 is not just another biomarker but is an important regulator of the function of LSCs in <italic>Pten</italic>-null T-ALL. HAVCR2 is directly regulated by SPI1 and serves as an important component of the β-catenin-SPI1-HAVCR2 regulatory circuit, which is essential for maintaining the LSC-specific expression of SPI1 and LSC ‘stemness’ (<xref ref-type="fig" rid="fig4">Figures 4</xref>–<xref ref-type="fig" rid="fig5">5</xref> and <xref ref-type="fig" rid="fig7">7</xref>–<xref ref-type="fig" rid="fig8">8</xref>). HAVCR2 can also serve as an LSC-specific target (<xref ref-type="fig" rid="fig11">Figures 11</xref>–<xref ref-type="fig" rid="fig12">12</xref>); this finding is similar to that in a recent AML publication (<xref ref-type="bibr" rid="bib30">Kikushige and Akashi, 2012</xref>; <xref ref-type="bibr" rid="bib31">Kikushige et al., 2015</xref>).</p><p>PTEN and the PI3K/AKT/mTOR pathway controlled by PTEN are critical for the etiology of human T-ALL (<xref ref-type="bibr" rid="bib24">Gutierrez et al., 2009</xref>; <xref ref-type="bibr" rid="bib33">Larson Gedman et al., 2009</xref>; <xref ref-type="bibr" rid="bib36">Liu et al., 2017</xref>; <xref ref-type="bibr" rid="bib37">Maser et al., 2007</xref>; <xref ref-type="bibr" rid="bib40">Palomero et al., 2007</xref>), and our study may illuminate the understanding and treatment of T-ALLs associated with PTEN loss or PI3K activation. We demonstrate that <italic>SPI1</italic> expression is upregulated by β-catenin and silenced by DNA methylation in human T-ALL cell lines, similar to the findings in the <italic>Pten</italic>-null T-ALL model (<xref ref-type="fig" rid="fig9">Figures 9</xref>–<xref ref-type="fig" rid="fig10">10</xref>). SPI1 also controls the expression of <italic>HAVCR2</italic> and other LSC signature genes in human T-ALL cell lines and clinical samples (<xref ref-type="fig" rid="fig5">Figure 5</xref>). However, whether the β-catenin-SPI1-HAVCR2 regulatory circuit also presents in human T-ALLs, especially the ETP T-ALL subtype, and determines LSC activity needs follow-up study using human T-ALL samples and PDX models. Such information may be used for the molecular classification of human T-ALLs, identifying human T-ALL LSCs and designing targeted treatment, as we showed in the mouse model. As HAVCR2<sup>high</sup> LSCs can be detected in the peripheral blood of leukemic mice (our unpublished data), further investigation is worthwhile to explore the potential use of this approach as a noninvasive strategy for stratifying T-ALL and monitoring the treatment response.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type <break/>(species) <break/>or resource</th><th valign="top">Designation</th><th valign="top">Source or <break/>reference</th><th valign="top">Identifiers</th><th valign="top">Additional <break/>information</th></tr></thead><tbody><tr><td valign="top">Strain, <break/>strain <break/>background <break/>(<italic>Mus musculus</italic>)</td><td valign="top"><italic>Cdh5-Cre<sup>+</sup>;</italic> <break/><italic>Pten<sup>l</sup><sup>oxP/loxP</sup>;</italic> <break/><italic>Rosa26<sup>floxedSTOP</sup>-LacZ<sup>+</sup></italic></td><td valign="top">(<xref ref-type="bibr" rid="bib19">Guo et al., 2008</xref>)</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Strain, strain <break/>background <break/>(<italic>Mus musculus</italic>)</td><td valign="top"><italic>Spi1<sup>loxP/loxP</sup></italic></td><td valign="top">(<xref ref-type="bibr" rid="bib11">Dakic et al., 2005</xref>)</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Strain, strain <break/>background <break/>(<italic>Mus musculus</italic>)</td><td valign="top"><italic>Spi1-GFP</italic></td><td valign="top">(<xref ref-type="bibr" rid="bib39">Nutt et al., 2005</xref>)</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Strain, strain <break/>background <break/>(<italic>Mus musculus</italic>)</td><td valign="top"><italic>Pten/Spi1</italic> <break/><italic>double KO</italic></td><td valign="top">This Paper</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Cell line <break/>(<italic>Homo sapiens</italic>)</td><td valign="top">KE-37</td><td valign="top">Deutsche <break/>Sammlung von <break/>Mikroorganismen <break/>und Zellkulturen <break/>(DSMZ)</td><td valign="top">ACC-46, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_1327">CVCL_1327</ext-link></td><td valign="top"/></tr><tr><td valign="top">Cell line <break/>(<italic>Homo sapiens</italic>)</td><td valign="top">Jurkat</td><td valign="top">(<xref ref-type="bibr" rid="bib48">Schubbert et al., 2014</xref>)</td><td valign="top"/><td valign="top">Received <break/>Drs. G. Cheng at <break/>UCLA</td></tr><tr><td valign="top">Cell line <break/>(<italic>Homo sapiens</italic>)</td><td valign="top">CEM</td><td valign="top">(<xref ref-type="bibr" rid="bib48">Schubbert et al., 2014</xref>)</td><td valign="top"/><td valign="top">Received <break/>C. Radu at UCLA</td></tr><tr><td valign="top">Cell line <break/>(<italic>Homo sapiens</italic>)</td><td valign="top">HEK 293T</td><td valign="top">American Type Culture Collection <break/>(ATCC)</td><td valign="top">CRL-3216, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_0063">CVCL_0063</ext-link></td><td valign="top"/></tr><tr><td valign="top">Cell line <break/>(<italic>Mus musculus</italic>)</td><td valign="top">HE001</td><td valign="top">(<xref ref-type="bibr" rid="bib48">Schubbert et al., 2014</xref>).</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">TER119- <break/>APC-Cy7</td><td valign="top">Biolegend</td><td valign="top">116223</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">B220-APC-Cy7</td><td valign="top">Biolegend</td><td valign="top">103224</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">CD45-PE</td><td valign="top">Biolegend</td><td valign="top">103108</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">CD3-PE-Cy7</td><td valign="top">Biolegend</td><td valign="top">100320</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">c-Kit-APC</td><td valign="top">Biolegend</td><td valign="top">105812</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">HAVCR2-PE</td><td valign="top">Biolegend</td><td valign="top">134004</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">ITGAX-FITC</td><td valign="top">Biolegend</td><td valign="top">117306</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">Mac-1-PB</td><td valign="top">Biolegend</td><td valign="top">101224</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">Gr-1-APC</td><td valign="top">Biolegend</td><td valign="top">108412</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">SPI1-PE</td><td valign="top">Biolegend</td><td valign="top">681308</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">MYC</td><td valign="top">Cell Signaling <break/>Technology</td><td valign="top">5605S</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">Nonphospho <break/>(active)-β- <break/>catenin</td><td valign="top">Cell Signaling <break/>Technology</td><td valign="top">70034 s</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">rabbit IgG</td><td valign="top">Cell Signaling <break/>Technology</td><td valign="top">3900 s</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">Phospho- <break/>NF-κB p65</td><td valign="top">Cell Signaling <break/>Technology</td><td valign="top">3033 s</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">SPI1</td><td valign="top">Cell Signaling <break/>Technology</td><td valign="top">2258 s</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">Phospho- <break/>GSK-3β</td><td valign="top">Cell Signaling <break/>Technology</td><td valign="top">5558 s</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">HAVCR2</td><td valign="top">Abcam</td><td valign="top">ab185703</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">HAVCR2</td><td valign="top">BioxCell</td><td valign="top">RMT3-23</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">IgG</td><td valign="top">BioxCell</td><td valign="top">2A3</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">Fluorescein (FITC) <break/>AffiniPure <break/>Fab Fragment <break/>Donkey Anti-Rabbit <break/>IgG (H + L)</td><td valign="top">Jackson <break/>Immuno <break/>Research</td><td valign="top">711-097-003</td><td valign="top"/></tr><tr><td valign="top">Chemical <break/>compound, <break/>drug</td><td valign="top">Rapamycin</td><td valign="top">LC <break/>laboratories</td><td valign="top">R-5000</td><td valign="top"/></tr><tr><td valign="top">Chemical <break/>compound, <break/>drug <break/></td><td valign="top">DB1976</td><td valign="top">(<xref ref-type="bibr" rid="bib5">Belver and Ferrando, 2016</xref>)</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Chemical <break/>compound, <break/>drug</td><td valign="top">5-AZ</td><td valign="top">Selleck</td><td valign="top">S1782</td><td valign="top"/></tr><tr><td valign="top">Chemical <break/>compound, <break/>drug</td><td valign="top">BAY10 <break/>82439</td><td valign="top">(<xref ref-type="bibr" rid="bib25">Hill et al., 2017</xref>)</td><td valign="top"/><td valign="top">Provided by <break/>Bayer <break/>Pharmaceuticals</td></tr><tr><td valign="top">Chemical <break/>compound, <break/>drug</td><td valign="top">BAY 6060</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Provided <break/>by Bayer <break/>Pharmaceuticals</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Mice</title><p>The <italic>Cdh5-Cre<sup>+</sup>;Pten<sup>loxP/loxP</sup>;Rosa26<sup>floxedSTOP</sup>-LacZ<sup>+</sup></italic> floxedSTOP-LacZ line was described previously (<xref ref-type="bibr" rid="bib19">Guo et al., 2008</xref>; <xref ref-type="bibr" rid="bib20">Guo et al., 2011</xref>; <xref ref-type="bibr" rid="bib48">Schubbert et al., 2014</xref>). The <italic>Spi1<sup>loxP/loxP</sup></italic> and <italic>Spi1-GFP</italic> mouse lines were kindly provided by Dr. Stephen L. Nutt. Mouse genotypes were determined by genomic PCR analyses with the primer sets listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary File 1</xref>. Animal housing, breeding, and surgical procedures were approved by the Ethics Committee under ID LSC-WuH-1 and conducted in accordance with the regulations of the Division of Laboratory Animal Medicine at Peking University.</p></sec><sec id="s4-2"><title>Cell lines</title><p>The KE-37 human T-ALL cell line was purchased from DMSZ, CEM and Jurkat cell lines were generously provided by C. Radu and Drs. G. Cheng at UCLA, respectively. All of the human T-ALL cell lines were maintained in 1640 (Life Technologies) supplemented with 10% FBS, penicillin, and streptomycin. The <italic>Pten</italic>-null T-ALL cell line (HE001) was generated previously reported, and cultured in DMEM (Life Technologies) added with 20% FBS(Omega Scientific), 10 ng/mL IL-2, and 10 ng/mL IL-7 (both Invitrogen), 10 mmol/L HEPES, nonessential amino acids, sodium pyruvate, glutamine, penicillin, and streptomycin (Life Technologies), and 2-mercaptoethanol (<inline-formula><mml:math id="inf1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>β</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>-ME; Sigma)(<xref ref-type="bibr" rid="bib48">Schubbert et al., 2014</xref>). All cell lines were maintained according to the manufacturer recommendations or previous publications. CEM, Jurkat, HEK293, and KE-37 cells were authenticated by the providers and independently authenticated (via Hi-C, WES and RNAseq analyses for genome-wide alteration, mutation signatures and gene expression profiles) in the lab. All lines tested negative for mycoplasma.</p></sec><sec id="s4-3"><title>Fluorescence-activated cell sorting (FACS) analyses</title><p>FACS analyses were performed on BD LSR Fortessa or Influx system from BD Biosciences. The numbers of leukemia blasts, LSC-enriched subpopulations, and HAVCR2/ITGAX subgroups, as well as intracellular protein levels, were analyzed as described previously (<xref ref-type="bibr" rid="bib19">Guo et al., 2008</xref>; <xref ref-type="bibr" rid="bib20">Guo et al., 2011</xref>; <xref ref-type="bibr" rid="bib48">Schubbert et al., 2014</xref>).</p></sec><sec id="s4-4"><title>Bulk RNA-seq analysis</title><p>For bulk RNA-seq analysis, total RNA was extracted from FACS-sorted cells using a RNeasy Micro Kit (Qiagen, 74004). Strand-specific libraries were generated using an NEBNext Ultra RNA Library Prep Kit (NEB, E7530) following the manufacturer’s protocol. Libraries of 350±20 bp were obtained, and the quality was determined using a Fragment Analyzer system (Advanced Analytical).</p><p>Barcoded libraries were subjected to 150 bp paired-end sequencing on an Illumina HiSeq 2500, and the paired-end reads were aligned to the mouse reference genome (Version mm9 from UCSC) using Tophat (v2.0.13)(<xref ref-type="bibr" rid="bib60">Trapnell et al., 2009</xref>). The expression value was generated as the number of fragments per kilobase of transcript per million mapped reads (FPKM) using Cufflinks (v2.2.1) (<xref ref-type="bibr" rid="bib61">Trapnell et al., 2012</xref>).</p></sec><sec id="s4-5"><title>Single-cell RNA-seq analysis</title><p>For single-cell RNA-seq analysis, we essentially followed a published protocol (<xref ref-type="bibr" rid="bib34">Li et al., 2017</xref>). Raw reads were processed as previously reported (<xref ref-type="bibr" rid="bib34">Li et al., 2017</xref>; <xref ref-type="bibr" rid="bib60">Trapnell et al., 2009</xref>) to generate expression values. Low-quality cells with less than 10,000 reads or less than 3000 covered genes were filtered out. Genes with a mean expression (TPM) value of less than one were discarded, leaving 276 cells and 12972 genes for further analysis. The unique gene set was then used for PCA, t-SNE, and pseudotime analyses (<xref ref-type="bibr" rid="bib42">Qiu et al., 2017a</xref>; <xref ref-type="bibr" rid="bib43">Qiu et al., 2017b</xref>; <xref ref-type="bibr" rid="bib62">Trapnell et al., 2014</xref>). Differentially expressed genes were identified by SCDE (<xref ref-type="bibr" rid="bib15">Fan et al., 2016</xref>; <xref ref-type="bibr" rid="bib28">Kharchenko et al., 2014</xref>), and genes with Z &gt; 4 were selected. Gene Ontology analysis was performed by Cluster Profiler (<xref ref-type="bibr" rid="bib67">Yu et al., 2012</xref>), followed by Gene Set Enrichment Analysis (GSEA)(<xref ref-type="bibr" rid="bib56">Subramanian et al., 2005</xref>) to identify gene sets that show significant differences between the blast and HAVCR2<sup>high</sup>subgroups.</p></sec><sec id="s4-6"><title>Transplantation assay</title><p><italic>Pten-null</italic> T-ALL cells harvested from primary <italic>Pten-null</italic> T-ALL mice were FACS-sorted and diluted before transplantation, as described previously (<xref ref-type="bibr" rid="bib19">Guo et al., 2008</xref>). Leukemia development was monitored daily by physical appearance, and weekly by peripheral blood smear and FACS analysis.. T-ALL was confirmed if the bone marrow or peripheral blood contained 20% leukemic blasts (<xref ref-type="bibr" rid="bib19">Guo et al., 2008</xref>).</p><p>For human T-ALL cell transplantation, CEM cells were treated with 5 μM 5-AZ or PBS for 6 days <italic>in vitro</italic>, and an equal number of untreated and treated cells were then transplanted by tail vein injection into NSG recipients.</p></sec><sec id="s4-7"><title>Real-time PCR</title><p>Total RNA was isolated using the RNeasy Micro Kit (Qiagen, 74004) and was reverse transcribed into cDNA using a HiScript II Q RT SuperMix for qPCR Kit (Vazyme, R223-01). Gene expression levels were measured with quantitative real-time PCR using a HiScript II One Step RT-PCR Kit (Vazyme, P611-01) and a CFX Real-Time PCR detection system (Bio-Rad). All expression data were normalized to<italic>β</italic>-actin expression, and the relative expression levels were derived from the delta-delta Ct values using CFX software (Bio-Rad). For the primer sequences used, please see <xref ref-type="supplementary-material" rid="supp2">Supplementary File 2</xref>.</p></sec><sec id="s4-8"><title>Plasmid construction</title><p>The full-length <italic>Spi1</italic> sequence was PCR-amplified from cDNAs generated from HAVCR2<sup>high</sup> cells (primers: EcoRI-SPI1-Forward 5’-GAATTCATGTTACAGGCGTGCAAAATGGAAG-3’ and XhoI-SPI1-Reverse 5’-CTCGAGTCAGTGGGGCGGGAGGCG-3’). The PCR products were purified and cloned into the MSCV-IRES-EGFP vector, generously provided by Dr. Owen Witt of UCLA, and the sequence was confirmed. The pll3.7-shSPI1 and control constructs were kindly provided by Dr. Junwu Zhang of the Chinese Academy of Medical Sciences and Peking Union Medical College, PLVX-IRES-RFP plasmid and PLVX-active-β-catenin (S33A, S37A, S45A) plasmid were kindly provided by Dr. Wei Guo of Tsinghua University.</p></sec><sec id="s4-9"><title>Western blot analysis</title><p>To quantify the protein levels of MYC and SPI1, Western blotting was performed as described previously (<xref ref-type="bibr" rid="bib48">Schubbert et al., 2014</xref>) and the membranes were probed with antibodies against MYC (5605s),and SPI1(2258s) from Cell Signaling Technology, using HAVCR2 (ab185703) antibody from abcam, <italic>β</italic>-actin (7210,Santa Cruz) as a loading control.</p></sec><sec id="s4-10"><title>Inhibitor and antibody treatments</title><p>Two-month-old <italic>Pten</italic>-null T-ALL leukemic mice were treated with 1) a daily dose of rapamycin (4 mg/kg, i.p; LC laboratories), DB1976 (2.5 mg/kg, oral; synthesized by Dr. Lei’s laboratory), or a combination of the two drugs; 2) a daily dose of BAY1082439 (75 mg/kg, oral; provided by Bayer Company), BAY6060(10 mg/kg, oral; provided by Bayer Company), or a combination of the two drugs; and 3) a daily dose of rapamycin (4 mg/kg, i.p; LC Laboratories) with twice weekly IgG (200 µg, i.p; 2A3,BioxCell) control or monoclonal anti-HAVCR2 (200 µg, i.p; RMT3-23,BioxCell) antibody. The durations of the treatments are indicated in <xref ref-type="fig" rid="fig11s1">Figure 11—figure supplement 1</xref>. HE and immunohistochemical(IHC) analyses were performed as described (<xref ref-type="bibr" rid="bib19">Guo et al., 2008</xref>).</p><p>For 5-AZ (S1782, Selleck) treatment, 6-week-old <italic>Pten</italic>-null T-ALL mice were treated with either vehicle or 5-AZ (1.25 mg/kg, i.p.; 3 days per week) for 2 weeks before intracellular FACS analysis.</p></sec><sec id="s4-11"><title>RRBS library preparation</title><p>Blast- and LSC-enriched subpopulations were collected by FACS sorting, and genomic DNA was extracted using a DNA micro kit or a DNA mini kit (Qiagen). The RRBS library was prepared according to a previous publication (<xref ref-type="bibr" rid="bib51">Smallwood and Kelsey, 2012</xref>). Genomic DNA was digested with MspI (Fermentas), followed by end repair, adapter ligation and bisulfite modification (Qiagen, #59104). The converted DNA library was sequenced on a HiSeq 4000 (Illumina) after two-round PCR amplification and size selection.</p></sec><sec id="s4-12"><title>DNA methylation analysis</title><p>BS-seq reads were aligned to the reference genome (mm9) by BS-Seeker2 (<xref ref-type="bibr" rid="bib21">Guo et al., 2013</xref>). The lollipop plot and region-specific distribution profiles were generated by CGmap Tools (<xref ref-type="bibr" rid="bib23">Guo et al., 2018</xref>). The methylation status of murine and human SPI1 promoter CpG islands was determined according to (<xref ref-type="bibr" rid="bib16">Fernández-Nestosa et al., 2013</xref>).</p></sec><sec id="s4-13"><title>Conventional bisulfite sequencing</title><p>For bisulfite conversion, genomic DNA was treated with an EZ-DNA Methylation-Direct Kit (D5021, Zymo Research) according to the manufacturer’s protocol. The converted DNA was subjected to PCR amplification and cloned into a pEASY-T1 Simple cloning vector (Transgene Biotech). The bisulfite primers for the mouse and human promoters were described previously (<xref ref-type="bibr" rid="bib16">Fernández-Nestosa et al., 2013</xref>; <xref ref-type="bibr" rid="bib57">Tatetsu et al., 2007</xref>)(Table S2). Individual clones were sequenced by Sanger sequencing, and the data were analyzed by the online software Quma (<ext-link ext-link-type="uri" xlink:href="http://quma.cdb.riken.jp">http://quma.cdb.riken.jp</ext-link>).</p></sec><sec id="s4-14"><title>Chromatin immunoprecipitation (ChIP)</title><p>Approximately 5 × 10<sup>6</sup> Blast-EGFP and Blast-SPI1 cells were used, and ChIP analysis was performed using a Zymo-Spin ChIP Kit (D5210, Zymo Research). The antibodies used for the ChIP assays were anti-SPI1 (sc-352, Santa Cruz) and normal rabbit IgG (2729, Cell Signaling Technology). The enriched regions were quantified by qPCR using the primers described in <xref ref-type="supplementary-material" rid="supp2">Supplementary File 2</xref>.</p></sec><sec id="s4-15"><title>Data access</title><p>All the Bulk RNA-seq, Single cell RNA-seq and BiSulfite-seq data for this study are deposited in NCBI Gene Expression Omnibus (GEO; accession # GSE115356; <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115356">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115356</ext-link>).</p></sec><sec id="s4-16"><title>Statistical analysis</title><p>GraphPad Prism software was used to calculate the means and standard deviations (SDs). The <italic>t</italic>-test or two-way ANOVA was used to determine statistical significance, and p&lt;0.05 was considered statistically significant. The data are presented as the means ± SDs.</p></sec></sec></body><back><sec id="s6" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>is an employee of Bayer AG</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con4"><p>Software, Formal analysis, Writing—review and editing</p></fn><fn fn-type="con" id="con5"><p>Data curation, Formal analysis, Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con6"><p>Software, Formal analysis, Writing—review and editing</p></fn><fn fn-type="con" id="con7"><p>Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con8"><p>Investigation</p></fn><fn fn-type="con" id="con9"><p>Investigation</p></fn><fn fn-type="con" id="con10"><p>Investigation, Writing—review and editing, Providing BAY1082439 and BAY6060</p></fn><fn fn-type="con" id="con11"><p>Supervision, Funding acquisition, Project administration, Writing—review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Resources, Supervision, Funding acquisition, Writing—original draft, Project administration, Writing—review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All experimental protocols were approved by the Peking University Animal Care and Use Committee (IACUC).This study were approved by the Peking University Animal Care and Use Committee (LSC-WuH-1).</p></fn></fn-group></sec><sec id="s5" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><object-id pub-id-type="doi">10.7554/eLife.38314.020</object-id><label>Supplementary File 1.</label><caption><title>Primers used for genotyping in this study.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-38314-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="supp2"><object-id pub-id-type="doi">10.7554/eLife.38314.021</object-id><label>Supplementary File 2.</label><caption><title>Primers used for q-PCR in this study.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-38314-supp2-v2.xlsx"/></supplementary-material><supplementary-material id="supp3"><object-id pub-id-type="doi">10.7554/eLife.38314.022</object-id><label>Supplementary File 3.</label><caption><title>List of FPKM for Bulk RNA-seq in T-ALL and genes list of the yellow module reported in the <xref ref-type="fig" rid="fig1">Figure 1A</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-38314-supp3-v2.xlsx"/></supplementary-material><supplementary-material id="supp4"><object-id pub-id-type="doi">10.7554/eLife.38314.023</object-id><label>Supplementary File 4.</label><caption><title>The genes list of the HAVCR2<sup>high</sup> signature genes (1079) and SPI1 target genes (710) reported in the <xref ref-type="fig" rid="fig4">Figure 4A</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-38314-supp4-v2.xlsx"/></supplementary-material><supplementary-material id="transrepform"><object-id pub-id-type="doi">10.7554/eLife.38314.024</object-id><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-38314-transrepform-v2.docx"/></supplementary-material><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All the Bulk RNA-seq, Single cell RNA-seq and BiSulfite-seq data for this study are deposited in NCBI Gene Expression Omnibus under the accession number GSE115356.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><data-title>T-ALL Leukemia Stem Cell</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115356">GSE115356</pub-id></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Van</surname><given-names>Vlierberghe P</given-names></name><name><surname>Ambesi-Impiombato</surname><given-names>A</given-names></name><name><surname>Perez-Garcia</surname><given-names>A</given-names></name><name><surname>Haydu</surname><given-names>JE</given-names></name><name><surname>Rigo</surname><given-names>I</given-names></name><name><surname>Hadler</surname><given-names>M</given-names></name><name><surname>Tosello</surname><given-names>V</given-names></name><name><surname>Della</surname><given-names>Gatta G</given-names></name><name><surname>Paietta</surname><given-names>E</given-names></name><name><surname>Racevskis</surname><given-names>J</given-names></name><name><surname>Wiernik</surname><given-names>PH</given-names></name><name><surname>Luger</surname><given-names>SM</given-names></name><name><surname>Rowe</surname><given-names>JM</given-names></name><name><surname>Rue</surname><given-names>M</given-names></name><name><surname>Ferrando</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2011">2011</year><data-title>Gene Expression Profile of 57 human T-ALL samples collected in human clinical trial E2993</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE33469">GSE33469</pub-id></element-citation></p></sec></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname> <given-names>MK</given-names></name><name><surname>Weiss</surname> <given-names>AH</given-names></name><name><surname>Hernandez-Hoyos</surname> <given-names>G</given-names></name><name><surname>Dionne</surname> <given-names>CJ</given-names></name><name><surname>Rothenberg</surname> <given-names>EV</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Constitutive expression of PU.1 in fetal hematopoietic progenitors blocks T cell development at the pro-T cell stage</article-title><source>Immunity</source><volume>16</volume><fpage>285</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(02)00277-7</pub-id><pub-id pub-id-type="pmid">11869688</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antony-Debré</surname> <given-names>I</given-names></name><name><surname>Paul</surname> <given-names>A</given-names></name><name><surname>Leite</surname> <given-names>J</given-names></name><name><surname>Mitchell</surname> <given-names>K</given-names></name><name><surname>Kim</surname> <given-names>HM</given-names></name><name><surname>Carvajal</surname> <given-names>LA</given-names></name><name><surname>Todorova</surname> <given-names>TI</given-names></name><name><surname>Huang</surname> <given-names>K</given-names></name><name><surname>Kumar</surname> <given-names>A</given-names></name><name><surname>Farahat</surname> <given-names>AA</given-names></name><name><surname>Bartholdy</surname> <given-names>B</given-names></name><name><surname>Narayanagari</surname> <given-names>SR</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Ambesi-Impiombato</surname> <given-names>A</given-names></name><name><surname>Ferrando</surname> <given-names>AA</given-names></name><name><surname>Mantzaris</surname> <given-names>I</given-names></name><name><surname>Gavathiotis</surname> <given-names>E</given-names></name><name><surname>Verma</surname> <given-names>A</given-names></name><name><surname>Will</surname> <given-names>B</given-names></name><name><surname>Boykin</surname> <given-names>DW</given-names></name><name><surname>Wilson</surname> <given-names>WD</given-names></name><name><surname>Poon</surname> <given-names>GM</given-names></name><name><surname>Steidl</surname> <given-names>U</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Pharmacological inhibition of the transcription factor PU.1 in leukemia</article-title><source>Journal of Clinical Investigation</source><volume>127</volume><fpage>4297</fpage><lpage>4313</lpage><pub-id pub-id-type="doi">10.1172/JCI92504</pub-id><pub-id pub-id-type="pmid">29083320</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atak</surname> <given-names>ZK</given-names></name><name><surname>Gianfelici</surname> <given-names>V</given-names></name><name><surname>Hulselmans</surname> <given-names>G</given-names></name><name><surname>De Keersmaecker</surname> <given-names>K</given-names></name><name><surname>Devasia</surname> <given-names>AG</given-names></name><name><surname>Geerdens</surname> <given-names>E</given-names></name><name><surname>Mentens</surname> <given-names>N</given-names></name><name><surname>Chiaretti</surname> <given-names>S</given-names></name><name><surname>Durinck</surname> <given-names>K</given-names></name><name><surname>Uyttebroeck</surname> <given-names>A</given-names></name><name><surname>Vandenberghe</surname> <given-names>P</given-names></name><name><surname>Wlodarska</surname> <given-names>I</given-names></name><name><surname>Cloos</surname> <given-names>J</given-names></name><name><surname>Foà</surname> <given-names>R</given-names></name><name><surname>Speleman</surname> <given-names>F</given-names></name><name><surname>Cools</surname> <given-names>J</given-names></name><name><surname>Aerts</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia</article-title><source>PLoS Genetics</source><volume>9</volume><elocation-id>e1003997</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1003997</pub-id><pub-id pub-id-type="pmid">24367274</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batlle</surname> <given-names>E</given-names></name><name><surname>Clevers</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cancer stem cells revisited</article-title><source>Nature Medicine</source><volume>23</volume><fpage>1124</fpage><lpage>1134</lpage><pub-id pub-id-type="doi">10.1038/nm.4409</pub-id><pub-id pub-id-type="pmid">28985214</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belver</surname> <given-names>L</given-names></name><name><surname>Ferrando</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The genetics and mechanisms of T cell acute lymphoblastic leukaemia</article-title><source>Nature Reviews Cancer</source><volume>16</volume><fpage>494</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1038/nrc.2016.63</pub-id><pub-id pub-id-type="pmid">27451956</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackburn</surname> <given-names>JS</given-names></name><name><surname>Liu</surname> <given-names>S</given-names></name><name><surname>Wilder</surname> <given-names>JL</given-names></name><name><surname>Dobrinski</surname> <given-names>KP</given-names></name><name><surname>Lobbardi</surname> <given-names>R</given-names></name><name><surname>Moore</surname> <given-names>FE</given-names></name><name><surname>Martinez</surname> <given-names>SA</given-names></name><name><surname>Chen</surname> <given-names>EY</given-names></name><name><surname>Lee</surname> <given-names>C</given-names></name><name><surname>Langenau</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Clonal evolution enhances leukemia-propagating cell frequency in T cell acute lymphoblastic leukemia through Akt/mTORC1 pathway activation</article-title><source>Cancer Cell</source><volume>25</volume><fpage>366</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2014.01.032</pub-id><pub-id pub-id-type="pmid">24613413</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonnet</surname> <given-names>D</given-names></name><name><surname>Dick</surname> <given-names>JE</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell</article-title><source>Nature Medicine</source><volume>3</volume><fpage>730</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1038/nm0797-730</pub-id><pub-id pub-id-type="pmid">9212098</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burger</surname> <given-names>R</given-names></name><name><surname>Hansen-Hagge</surname> <given-names>TE</given-names></name><name><surname>Drexler</surname> <given-names>HG</given-names></name><name><surname>Gramatzki</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Heterogeneity of T-acute lymphoblastic leukemia (T-ALL) cell lines: suggestion for classification by immunophenotype and T-cell receptor studies</article-title><source>Leukemia Research</source><volume>23</volume><fpage>19</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/S0145-2126(98)00133-7</pub-id><pub-id pub-id-type="pmid">9933131</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Champhekar</surname> <given-names>A</given-names></name><name><surname>Damle</surname> <given-names>SS</given-names></name><name><surname>Freedman</surname> <given-names>G</given-names></name><name><surname>Carotta</surname> <given-names>S</given-names></name><name><surname>Nutt</surname> <given-names>SL</given-names></name><name><surname>Rothenberg</surname> <given-names>EV</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Regulation of early T-lineage gene expression and developmental progression by the progenitor cell transcription factor PU.1</article-title><source>Genes &amp; Development</source><volume>29</volume><fpage>832</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1101/gad.259879.115</pub-id><pub-id pub-id-type="pmid">25846797</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname> <given-names>PP</given-names></name><name><surname>Jiang</surname> <given-names>H</given-names></name><name><surname>Dick</surname> <given-names>JE</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Leukemia-initiating cells in human T-lymphoblastic leukemia exhibit glucocorticoid resistance</article-title><source>Blood</source><volume>116</volume><fpage>5268</fpage><lpage>5279</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-06-292300</pub-id><pub-id pub-id-type="pmid">20810926</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dakic</surname> <given-names>A</given-names></name><name><surname>Metcalf</surname> <given-names>D</given-names></name><name><surname>Di Rago</surname> <given-names>L</given-names></name><name><surname>Mifsud</surname> <given-names>S</given-names></name><name><surname>Wu</surname> <given-names>L</given-names></name><name><surname>Nutt</surname> <given-names>SL</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>PU.1 regulates the commitment of adult hematopoietic progenitors and restricts granulopoiesis</article-title><source>The Journal of Experimental Medicine</source><volume>201</volume><fpage>1487</fpage><lpage>1502</lpage><pub-id pub-id-type="doi">10.1084/jem.20050075</pub-id><pub-id pub-id-type="pmid">15867096</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dakic</surname> <given-names>A</given-names></name><name><surname>Wu</surname> <given-names>L</given-names></name><name><surname>Nutt</surname> <given-names>SL</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Is PU.1 a dosage-sensitive regulator of haemopoietic lineage commitment and leukaemogenesis?</article-title><source>Trends in Immunology</source><volume>28</volume><fpage>108</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/j.it.2007.01.006</pub-id><pub-id pub-id-type="pmid">17267285</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dan</surname> <given-names>HC</given-names></name><name><surname>Cooper</surname> <given-names>MJ</given-names></name><name><surname>Cogswell</surname> <given-names>PC</given-names></name><name><surname>Duncan</surname> <given-names>JA</given-names></name><name><surname>Ting</surname> <given-names>JP</given-names></name><name><surname>Baldwin</surname> <given-names>AS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK</article-title><source>Genes &amp; Development</source><volume>22</volume><fpage>1490</fpage><lpage>1500</lpage><pub-id pub-id-type="doi">10.1101/gad.1662308</pub-id><pub-id pub-id-type="pmid">18519641</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dose</surname> <given-names>M</given-names></name><name><surname>Emmanuel</surname> <given-names>AO</given-names></name><name><surname>Chaumeil</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Sun</surname> <given-names>T</given-names></name><name><surname>Germar</surname> <given-names>K</given-names></name><name><surname>Aghajani</surname> <given-names>K</given-names></name><name><surname>Davis</surname> <given-names>EM</given-names></name><name><surname>Keerthivasan</surname> <given-names>S</given-names></name><name><surname>Bredemeyer</surname> <given-names>AL</given-names></name><name><surname>Sleckman</surname> <given-names>BP</given-names></name><name><surname>Rosen</surname> <given-names>ST</given-names></name><name><surname>Skok</surname> <given-names>JA</given-names></name><name><surname>Le Beau</surname> <given-names>MM</given-names></name><name><surname>Georgopoulos</surname> <given-names>K</given-names></name><name><surname>Gounari</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>β-Catenin induces T-cell transformation by promoting genomic instability</article-title><source>PNAS</source><volume>111</volume><fpage>391</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1073/pnas.1315752111</pub-id><pub-id pub-id-type="pmid">24371308</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname> <given-names>J</given-names></name><name><surname>Salathia</surname> <given-names>N</given-names></name><name><surname>Liu</surname> <given-names>R</given-names></name><name><surname>Kaeser</surname> <given-names>GE</given-names></name><name><surname>Yung</surname> <given-names>YC</given-names></name><name><surname>Herman</surname> <given-names>JL</given-names></name><name><surname>Kaper</surname> <given-names>F</given-names></name><name><surname>Fan</surname> <given-names>JB</given-names></name><name><surname>Zhang</surname> <given-names>K</given-names></name><name><surname>Chun</surname> <given-names>J</given-names></name><name><surname>Kharchenko</surname> <given-names>PV</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Characterizing transcriptional heterogeneity through pathway and gene set overdispersion analysis</article-title><source>Nature Methods</source><volume>13</volume><fpage>241</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3734</pub-id><pub-id pub-id-type="pmid">26780092</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernández-Nestosa</surname> <given-names>MJ</given-names></name><name><surname>Monturus</surname> <given-names>E</given-names></name><name><surname>Sánchez</surname> <given-names>Z</given-names></name><name><surname>Torres</surname> <given-names>FS</given-names></name><name><surname>Fernández</surname> <given-names>AF</given-names></name><name><surname>Fraga</surname> <given-names>MF</given-names></name><name><surname>Hernández</surname> <given-names>P</given-names></name><name><surname>Schvartzman</surname> <given-names>JB</given-names></name><name><surname>Krimer</surname> <given-names>DB</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>DNA methylation-mediated silencing of PU.1 in leukemia cells resistant to cell differentiation</article-title><source>SpringerPlus</source><volume>2</volume><elocation-id>392</elocation-id><pub-id pub-id-type="doi">10.1186/2193-1801-2-392</pub-id><pub-id pub-id-type="pmid">24010046</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrando</surname> <given-names>AA</given-names></name><name><surname>López-Otín</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Clonal evolution in leukemia</article-title><source>Nature Medicine</source><volume>23</volume><fpage>1135</fpage><lpage>1145</lpage><pub-id pub-id-type="doi">10.1038/nm.4410</pub-id><pub-id pub-id-type="pmid">28985206</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girardi</surname> <given-names>T</given-names></name><name><surname>Vicente</surname> <given-names>C</given-names></name><name><surname>Cools</surname> <given-names>J</given-names></name><name><surname>De Keersmaecker</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The genetics and molecular biology of T-ALL</article-title><source>Blood</source><volume>129</volume><fpage>1113</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.1182/blood-2016-10-706465</pub-id><pub-id pub-id-type="pmid">28115373</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname> <given-names>W</given-names></name><name><surname>Lasky</surname> <given-names>JL</given-names></name><name><surname>Chang</surname> <given-names>CJ</given-names></name><name><surname>Mosessian</surname> <given-names>S</given-names></name><name><surname>Lewis</surname> <given-names>X</given-names></name><name><surname>Xiao</surname> <given-names>Y</given-names></name><name><surname>Yeh</surname> <given-names>JE</given-names></name><name><surname>Chen</surname> <given-names>JY</given-names></name><name><surname>Iruela-Arispe</surname> <given-names>ML</given-names></name><name><surname>Varella-Garcia</surname> <given-names>M</given-names></name><name><surname>Wu</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation</article-title><source>Nature</source><volume>453</volume><fpage>529</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1038/nature06933</pub-id><pub-id pub-id-type="pmid">18463637</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname> <given-names>W</given-names></name><name><surname>Schubbert</surname> <given-names>S</given-names></name><name><surname>Chen</surname> <given-names>JY</given-names></name><name><surname>Valamehr</surname> <given-names>B</given-names></name><name><surname>Mosessian</surname> <given-names>S</given-names></name><name><surname>Shi</surname> <given-names>H</given-names></name><name><surname>Dang</surname> <given-names>NH</given-names></name><name><surname>Garcia</surname> <given-names>C</given-names></name><name><surname>Theodoro</surname> <given-names>MF</given-names></name><name><surname>Varella-Garcia</surname> <given-names>M</given-names></name><name><surname>Wu</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Suppression of leukemia development caused by PTEN loss</article-title><source>Proceedings of the National Academy of Sciences</source><volume>108</volume><fpage>1409</fpage><lpage>1414</lpage><pub-id pub-id-type="doi">10.1073/pnas.1006937108</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname> <given-names>W</given-names></name><name><surname>Fiziev</surname> <given-names>P</given-names></name><name><surname>Yan</surname> <given-names>W</given-names></name><name><surname>Cokus</surname> <given-names>S</given-names></name><name><surname>Sun</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>MQ</given-names></name><name><surname>Chen</surname> <given-names>PY</given-names></name><name><surname>Pellegrini</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>BS-Seeker2: a versatile aligning pipeline for bisulfite sequencing data</article-title><source>BMC Genomics</source><volume>14</volume><fpage>774</fpage><pub-id pub-id-type="doi">10.1186/1471-2164-14-774</pub-id><pub-id pub-id-type="pmid">24206606</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname> <given-names>W</given-names></name><name><surname>Chung</surname> <given-names>WY</given-names></name><name><surname>Qian</surname> <given-names>M</given-names></name><name><surname>Pellegrini</surname> <given-names>M</given-names></name><name><surname>Zhang</surname> <given-names>MQ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Characterizing the strand-specific distribution of non-CpG methylation in human pluripotent cells</article-title><source>Nucleic Acids Research</source><volume>42</volume><fpage>3009</fpage><lpage>3016</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt1306</pub-id><pub-id pub-id-type="pmid">24343027</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname> <given-names>W</given-names></name><name><surname>Zhu</surname> <given-names>P</given-names></name><name><surname>Pellegrini</surname> <given-names>M</given-names></name><name><surname>Zhang</surname> <given-names>MQ</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Ni</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>CGmapTools improves the precision of heterozygous SNV calls and supports allele-specific methylation detection and visualization in bisulfite-sequencing data</article-title><source>Bioinformatics</source><volume>34</volume><fpage>381-387</fpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btx595</pub-id><pub-id pub-id-type="pmid">28968643</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutierrez</surname> <given-names>A</given-names></name><name><surname>Sanda</surname> <given-names>T</given-names></name><name><surname>Grebliunaite</surname> <given-names>R</given-names></name><name><surname>Carracedo</surname> <given-names>A</given-names></name><name><surname>Salmena</surname> <given-names>L</given-names></name><name><surname>Ahn</surname> <given-names>Y</given-names></name><name><surname>Dahlberg</surname> <given-names>S</given-names></name><name><surname>Neuberg</surname> <given-names>D</given-names></name><name><surname>Moreau</surname> <given-names>LA</given-names></name><name><surname>Winter</surname> <given-names>SS</given-names></name><name><surname>Larson</surname> <given-names>R</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Protopopov</surname> <given-names>A</given-names></name><name><surname>Chin</surname> <given-names>L</given-names></name><name><surname>Pandolfi</surname> <given-names>PP</given-names></name><name><surname>Silverman</surname> <given-names>LB</given-names></name><name><surname>Hunger</surname> <given-names>SP</given-names></name><name><surname>Sallan</surname> <given-names>SE</given-names></name><name><surname>Look</surname> <given-names>AT</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia</article-title><source>Blood</source><volume>114</volume><fpage>647</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-02-206722</pub-id><pub-id pub-id-type="pmid">19458356</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname> <given-names>R</given-names></name><name><surname>Madureira</surname> <given-names>PA</given-names></name><name><surname>Ferreira</surname> <given-names>B</given-names></name><name><surname>Baptista</surname> <given-names>I</given-names></name><name><surname>Machado</surname> <given-names>S</given-names></name><name><surname>Colaço</surname> <given-names>L</given-names></name><name><surname>Dos Santos</surname> <given-names>M</given-names></name><name><surname>Liu</surname> <given-names>N</given-names></name><name><surname>Dopazo</surname> <given-names>A</given-names></name><name><surname>Ugurel</surname> <given-names>S</given-names></name><name><surname>Adrienn</surname> <given-names>A</given-names></name><name><surname>Kiss-Toth</surname> <given-names>E</given-names></name><name><surname>Isbilen</surname> <given-names>M</given-names></name><name><surname>Gure</surname> <given-names>AO</given-names></name><name><surname>Link</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>14687</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms14687</pub-id><pub-id pub-id-type="pmid">28276427</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>Y</given-names></name><name><surname>Smyth</surname> <given-names>GK</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays</article-title><source>Journal of Immunological Methods</source><volume>347</volume><fpage>70</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2009.06.008</pub-id><pub-id pub-id-type="pmid">19567251</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaveri</surname> <given-names>D</given-names></name><name><surname>Kastner</surname> <given-names>P</given-names></name><name><surname>Dembélé</surname> <given-names>D</given-names></name><name><surname>Nerlov</surname> <given-names>C</given-names></name><name><surname>Chan</surname> <given-names>S</given-names></name><name><surname>Kirstetter</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>β-Catenin activation synergizes with Pten loss and Myc overexpression in Notch-independent T-ALL</article-title><source>Blood</source><volume>122</volume><fpage>694</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-12-471904</pub-id><pub-id pub-id-type="pmid">23801632</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kharchenko</surname> <given-names>PV</given-names></name><name><surname>Silberstein</surname> <given-names>L</given-names></name><name><surname>Scadden</surname> <given-names>DT</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Bayesian approach to single-cell differential expression analysis</article-title><source>Nature Methods</source><volume>11</volume><fpage>740</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2967</pub-id><pub-id pub-id-type="pmid">24836921</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kikushige</surname> <given-names>Y</given-names></name><name><surname>Shima</surname> <given-names>T</given-names></name><name><surname>Takayanagi</surname> <given-names>S</given-names></name><name><surname>Urata</surname> <given-names>S</given-names></name><name><surname>Miyamoto</surname> <given-names>T</given-names></name><name><surname>Iwasaki</surname> <given-names>H</given-names></name><name><surname>Takenaka</surname> <given-names>K</given-names></name><name><surname>Teshima</surname> <given-names>T</given-names></name><name><surname>Tanaka</surname> <given-names>T</given-names></name><name><surname>Inagaki</surname> <given-names>Y</given-names></name><name><surname>Akashi</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells</article-title><source>Cell Stem Cell</source><volume>7</volume><fpage>708</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2010.11.014</pub-id><pub-id pub-id-type="pmid">21112565</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kikushige</surname> <given-names>Y</given-names></name><name><surname>Akashi</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia</article-title><source>Annals of the New York Academy of Sciences</source><volume>1266</volume><fpage>118</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2012.06550.x</pub-id><pub-id pub-id-type="pmid">22901263</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kikushige</surname> <given-names>Y</given-names></name><name><surname>Miyamoto</surname> <given-names>T</given-names></name><name><surname>Yuda</surname> <given-names>J</given-names></name><name><surname>Jabbarzadeh-Tabrizi</surname> <given-names>S</given-names></name><name><surname>Shima</surname> <given-names>T</given-names></name><name><surname>Takayanagi</surname> <given-names>S</given-names></name><name><surname>Niiro</surname> <given-names>H</given-names></name><name><surname>Yurino</surname> <given-names>A</given-names></name><name><surname>Miyawaki</surname> <given-names>K</given-names></name><name><surname>Takenaka</surname> <given-names>K</given-names></name><name><surname>Iwasaki</surname> <given-names>H</given-names></name><name><surname>Akashi</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A TIM-3/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression</article-title><source>Cell Stem Cell</source><volume>17</volume><fpage>341</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2015.07.011</pub-id><pub-id pub-id-type="pmid">26279267</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koyama</surname> <given-names>S</given-names></name><name><surname>Akbay</surname> <given-names>EA</given-names></name><name><surname>Li</surname> <given-names>YY</given-names></name><name><surname>Herter-Sprie</surname> <given-names>GS</given-names></name><name><surname>Buczkowski</surname> <given-names>KA</given-names></name><name><surname>Richards</surname> <given-names>WG</given-names></name><name><surname>Gandhi</surname> <given-names>L</given-names></name><name><surname>Redig</surname> <given-names>AJ</given-names></name><name><surname>Rodig</surname> <given-names>SJ</given-names></name><name><surname>Asahina</surname> <given-names>H</given-names></name><name><surname>Jones</surname> <given-names>RE</given-names></name><name><surname>Kulkarni</surname> <given-names>MM</given-names></name><name><surname>Kuraguchi</surname> <given-names>M</given-names></name><name><surname>Palakurthi</surname> <given-names>S</given-names></name><name><surname>Fecci</surname> <given-names>PE</given-names></name><name><surname>Johnson</surname> <given-names>BE</given-names></name><name><surname>Janne</surname> <given-names>PA</given-names></name><name><surname>Engelman</surname> <given-names>JA</given-names></name><name><surname>Gangadharan</surname> <given-names>SP</given-names></name><name><surname>Costa</surname> <given-names>DB</given-names></name><name><surname>Freeman</surname> <given-names>GJ</given-names></name><name><surname>Bueno</surname> <given-names>R</given-names></name><name><surname>Hodi</surname> <given-names>FS</given-names></name><name><surname>Dranoff</surname> <given-names>G</given-names></name><name><surname>Wong</surname> <given-names>KK</given-names></name><name><surname>Hammerman</surname> <given-names>PS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>10501</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms10501</pub-id><pub-id pub-id-type="pmid">26883990</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larson Gedman</surname> <given-names>A</given-names></name><name><surname>Chen</surname> <given-names>Q</given-names></name><name><surname>Kugel Desmoulin</surname> <given-names>S</given-names></name><name><surname>Ge</surname> <given-names>Y</given-names></name><name><surname>LaFiura</surname> <given-names>K</given-names></name><name><surname>Haska</surname> <given-names>CL</given-names></name><name><surname>Cherian</surname> <given-names>C</given-names></name><name><surname>Devidas</surname> <given-names>M</given-names></name><name><surname>Linda</surname> <given-names>SB</given-names></name><name><surname>Taub</surname> <given-names>JW</given-names></name><name><surname>Matherly</surname> <given-names>LH</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group</article-title><source>Leukemia</source><volume>23</volume><fpage>1417</fpage><lpage>1425</lpage><pub-id pub-id-type="doi">10.1038/leu.2009.64</pub-id><pub-id pub-id-type="pmid">19340001</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Dong</surname> <given-names>J</given-names></name><name><surname>Yan</surname> <given-names>L</given-names></name><name><surname>Yong</surname> <given-names>J</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Hu</surname> <given-names>Y</given-names></name><name><surname>Fan</surname> <given-names>X</given-names></name><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>Guo</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Zhu</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>R</given-names></name><name><surname>Yan</surname> <given-names>J</given-names></name><name><surname>Wei</surname> <given-names>Y</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>W</given-names></name><name><surname>Ren</surname> <given-names>Y</given-names></name><name><surname>Yuan</surname> <given-names>P</given-names></name><name><surname>Yan</surname> <given-names>Z</given-names></name><name><surname>Hu</surname> <given-names>B</given-names></name><name><surname>Guo</surname> <given-names>F</given-names></name><name><surname>Wen</surname> <given-names>L</given-names></name><name><surname>Tang</surname> <given-names>F</given-names></name><name><surname>Qiao</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Single-cell rna-seq analysis maps development of human germline cells and gonadal niche interactions</article-title><source>Cell Stem Cell</source><volume>20</volume><fpage>858</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2017.03.007</pub-id><pub-id pub-id-type="pmid">28457750</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberzon</surname> <given-names>A</given-names></name><name><surname>Subramanian</surname> <given-names>A</given-names></name><name><surname>Pinchback</surname> <given-names>R</given-names></name><name><surname>Thorvaldsdóttir</surname> <given-names>H</given-names></name><name><surname>Tamayo</surname> <given-names>P</given-names></name><name><surname>Mesirov</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Molecular signatures database (MSigDB) 3.0</article-title><source>Bioinformatics</source><volume>27</volume><fpage>1739</fpage><lpage>1740</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btr260</pub-id><pub-id pub-id-type="pmid">21546393</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Easton</surname> <given-names>J</given-names></name><name><surname>Shao</surname> <given-names>Y</given-names></name><name><surname>Maciaszek</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Wilkinson</surname> <given-names>MR</given-names></name><name><surname>McCastlain</surname> <given-names>K</given-names></name><name><surname>Edmonson</surname> <given-names>M</given-names></name><name><surname>Pounds</surname> <given-names>SB</given-names></name><name><surname>Shi</surname> <given-names>L</given-names></name><name><surname>Zhou</surname> <given-names>X</given-names></name><name><surname>Ma</surname> <given-names>X</given-names></name><name><surname>Sioson</surname> <given-names>E</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Rusch</surname> <given-names>M</given-names></name><name><surname>Gupta</surname> <given-names>P</given-names></name><name><surname>Pei</surname> <given-names>D</given-names></name><name><surname>Cheng</surname> <given-names>C</given-names></name><name><surname>Smith</surname> <given-names>MA</given-names></name><name><surname>Auvil</surname> <given-names>JG</given-names></name><name><surname>Gerhard</surname> <given-names>DS</given-names></name><name><surname>Relling</surname> <given-names>MV</given-names></name><name><surname>Winick</surname> <given-names>NJ</given-names></name><name><surname>Carroll</surname> <given-names>AJ</given-names></name><name><surname>Heerema</surname> <given-names>NA</given-names></name><name><surname>Raetz</surname> <given-names>E</given-names></name><name><surname>Devidas</surname> <given-names>M</given-names></name><name><surname>Willman</surname> <given-names>CL</given-names></name><name><surname>Harvey</surname> <given-names>RC</given-names></name><name><surname>Carroll</surname> <given-names>WL</given-names></name><name><surname>Dunsmore</surname> <given-names>KP</given-names></name><name><surname>Winter</surname> <given-names>SS</given-names></name><name><surname>Wood</surname> <given-names>BL</given-names></name><name><surname>Sorrentino</surname> <given-names>BP</given-names></name><name><surname>Downing</surname> <given-names>JR</given-names></name><name><surname>Loh</surname> <given-names>ML</given-names></name><name><surname>Hunger</surname> <given-names>SP</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Mullighan</surname> <given-names>CG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia</article-title><source>Nature Genetics</source><volume>49</volume><fpage>1211</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1038/ng.3909</pub-id><pub-id pub-id-type="pmid">28671688</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maser</surname> <given-names>RS</given-names></name><name><surname>Choudhury</surname> <given-names>B</given-names></name><name><surname>Campbell</surname> <given-names>PJ</given-names></name><name><surname>Feng</surname> <given-names>B</given-names></name><name><surname>Wong</surname> <given-names>KK</given-names></name><name><surname>Protopopov</surname> <given-names>A</given-names></name><name><surname>O'Neil</surname> <given-names>J</given-names></name><name><surname>Gutierrez</surname> <given-names>A</given-names></name><name><surname>Ivanova</surname> <given-names>E</given-names></name><name><surname>Perna</surname> <given-names>I</given-names></name><name><surname>Lin</surname> <given-names>E</given-names></name><name><surname>Mani</surname> <given-names>V</given-names></name><name><surname>Jiang</surname> <given-names>S</given-names></name><name><surname>McNamara</surname> <given-names>K</given-names></name><name><surname>Zaghlul</surname> <given-names>S</given-names></name><name><surname>Edkins</surname> <given-names>S</given-names></name><name><surname>Stevens</surname> <given-names>C</given-names></name><name><surname>Brennan</surname> <given-names>C</given-names></name><name><surname>Martin</surname> <given-names>ES</given-names></name><name><surname>Wiedemeyer</surname> <given-names>R</given-names></name><name><surname>Kabbarah</surname> <given-names>O</given-names></name><name><surname>Nogueira</surname> <given-names>C</given-names></name><name><surname>Histen</surname> <given-names>G</given-names></name><name><surname>Aster</surname> <given-names>J</given-names></name><name><surname>Mansour</surname> <given-names>M</given-names></name><name><surname>Duke</surname> <given-names>V</given-names></name><name><surname>Foroni</surname> <given-names>L</given-names></name><name><surname>Fielding</surname> <given-names>AK</given-names></name><name><surname>Goldstone</surname> <given-names>AH</given-names></name><name><surname>Rowe</surname> <given-names>JM</given-names></name><name><surname>Wang</surname> <given-names>YA</given-names></name><name><surname>Look</surname> <given-names>AT</given-names></name><name><surname>Stratton</surname> <given-names>MR</given-names></name><name><surname>Chin</surname> <given-names>L</given-names></name><name><surname>Futreal</surname> <given-names>PA</given-names></name><name><surname>DePinho</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers</article-title><source>Nature</source><volume>447</volume><fpage>966</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1038/nature05886</pub-id><pub-id pub-id-type="pmid">17515920</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munde</surname> <given-names>M</given-names></name><name><surname>Wang</surname> <given-names>S</given-names></name><name><surname>Kumar</surname> <given-names>A</given-names></name><name><surname>Stephens</surname> <given-names>CE</given-names></name><name><surname>Farahat</surname> <given-names>AA</given-names></name><name><surname>Boykin</surname> <given-names>DW</given-names></name><name><surname>Wilson</surname> <given-names>WD</given-names></name><name><surname>Poon</surname> <given-names>GM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Structure-dependent inhibition of the ETS-family transcription factor PU.1 by novel heterocyclic diamidines</article-title><source>Nucleic Acids Research</source><volume>42</volume><fpage>1379</fpage><lpage>1390</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt955</pub-id><pub-id pub-id-type="pmid">24157839</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nutt</surname> <given-names>SL</given-names></name><name><surname>Metcalf</surname> <given-names>D</given-names></name><name><surname>D'Amico</surname> <given-names>A</given-names></name><name><surname>Polli</surname> <given-names>M</given-names></name><name><surname>Wu</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Dynamic regulation of PU.1 expression in multipotent hematopoietic progenitors</article-title><source>The Journal of Experimental Medicine</source><volume>201</volume><fpage>221</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1084/jem.20041535</pub-id><pub-id pub-id-type="pmid">15657291</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palomero</surname> <given-names>T</given-names></name><name><surname>Sulis</surname> <given-names>ML</given-names></name><name><surname>Cortina</surname> <given-names>M</given-names></name><name><surname>Real</surname> <given-names>PJ</given-names></name><name><surname>Barnes</surname> <given-names>K</given-names></name><name><surname>Ciofani</surname> <given-names>M</given-names></name><name><surname>Caparros</surname> <given-names>E</given-names></name><name><surname>Buteau</surname> <given-names>J</given-names></name><name><surname>Brown</surname> <given-names>K</given-names></name><name><surname>Perkins</surname> <given-names>SL</given-names></name><name><surname>Bhagat</surname> <given-names>G</given-names></name><name><surname>Agarwal</surname> <given-names>AM</given-names></name><name><surname>Basso</surname> <given-names>G</given-names></name><name><surname>Castillo</surname> <given-names>M</given-names></name><name><surname>Nagase</surname> <given-names>S</given-names></name><name><surname>Cordon-Cardo</surname> <given-names>C</given-names></name><name><surname>Parsons</surname> <given-names>R</given-names></name><name><surname>Zúñiga-Pflücker</surname> <given-names>JC</given-names></name><name><surname>Dominguez</surname> <given-names>M</given-names></name><name><surname>Ferrando</surname> <given-names>AA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia</article-title><source>Nature Medicine</source><volume>13</volume><fpage>1203</fpage><lpage>1210</lpage><pub-id pub-id-type="doi">10.1038/nm1636</pub-id><pub-id pub-id-type="pmid">17873882</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Persad</surname> <given-names>S</given-names></name><name><surname>Troussard</surname> <given-names>AA</given-names></name><name><surname>McPhee</surname> <given-names>TR</given-names></name><name><surname>Mulholland</surname> <given-names>DJ</given-names></name><name><surname>Dedhar</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Tumor suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell/lymphoid enhancer factor 1-mediated transcriptional activation</article-title><source>The Journal of Cell Biology</source><volume>153</volume><fpage>1161</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1083/jcb.153.6.1161</pub-id><pub-id pub-id-type="pmid">11402061</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname> <given-names>X</given-names></name><name><surname>Hill</surname> <given-names>A</given-names></name><name><surname>Packer</surname> <given-names>J</given-names></name><name><surname>Lin</surname> <given-names>D</given-names></name><name><surname>Ma</surname> <given-names>YA</given-names></name><name><surname>Trapnell</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017a</year><article-title>Single-cell mRNA quantification and differential analysis with Census</article-title><source>Nature Methods</source><volume>14</volume><fpage>309</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4150</pub-id><pub-id pub-id-type="pmid">28114287</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname> <given-names>X</given-names></name><name><surname>Mao</surname> <given-names>Q</given-names></name><name><surname>Tang</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Chawla</surname> <given-names>R</given-names></name><name><surname>Pliner</surname> <given-names>HA</given-names></name><name><surname>Trapnell</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>Reversed graph embedding resolves complex single-cell trajectories</article-title><source>Nature Methods</source><volume>14</volume><fpage>979</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4402</pub-id><pub-id pub-id-type="pmid">28825705</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reya</surname> <given-names>T</given-names></name><name><surname>Morrison</surname> <given-names>SJ</given-names></name><name><surname>Clarke</surname> <given-names>MF</given-names></name><name><surname>Weissman</surname> <given-names>IL</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Stem cells, cancer, and cancer stem cells</article-title><source>Nature</source><volume>414</volume><fpage>105</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1038/35102167</pub-id><pub-id pub-id-type="pmid">11689955</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenbauer</surname> <given-names>F</given-names></name><name><surname>Wagner</surname> <given-names>K</given-names></name><name><surname>Kutok</surname> <given-names>JL</given-names></name><name><surname>Iwasaki</surname> <given-names>H</given-names></name><name><surname>Le Beau</surname> <given-names>MM</given-names></name><name><surname>Okuno</surname> <given-names>Y</given-names></name><name><surname>Akashi</surname> <given-names>K</given-names></name><name><surname>Fiering</surname> <given-names>S</given-names></name><name><surname>Tenen</surname> <given-names>DG</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1</article-title><source>Nature Genetics</source><volume>36</volume><fpage>624</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1038/ng1361</pub-id><pub-id pub-id-type="pmid">15146183</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenbauer</surname> <given-names>F</given-names></name><name><surname>Owens</surname> <given-names>BM</given-names></name><name><surname>Yu</surname> <given-names>L</given-names></name><name><surname>Tumang</surname> <given-names>JR</given-names></name><name><surname>Steidl</surname> <given-names>U</given-names></name><name><surname>Kutok</surname> <given-names>JL</given-names></name><name><surname>Clayton</surname> <given-names>LK</given-names></name><name><surname>Wagner</surname> <given-names>K</given-names></name><name><surname>Scheller</surname> <given-names>M</given-names></name><name><surname>Iwasaki</surname> <given-names>H</given-names></name><name><surname>Liu</surname> <given-names>C</given-names></name><name><surname>Hackanson</surname> <given-names>B</given-names></name><name><surname>Akashi</surname> <given-names>K</given-names></name><name><surname>Leutz</surname> <given-names>A</given-names></name><name><surname>Rothstein</surname> <given-names>TL</given-names></name><name><surname>Plass</surname> <given-names>C</given-names></name><name><surname>Tenen</surname> <given-names>DG</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1</article-title><source>Nature Genetics</source><volume>38</volume><fpage>27</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1038/ng1679</pub-id><pub-id pub-id-type="pmid">16311598</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothenberg</surname> <given-names>EV</given-names></name><name><surname>Kueh</surname> <given-names>HY</given-names></name><name><surname>Yui</surname> <given-names>MA</given-names></name><name><surname>Zhang</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Hematopoiesis and T-cell specification as a model developmental system</article-title><source>Immunological Reviews</source><volume>271</volume><fpage>72</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1111/imr.12417</pub-id><pub-id pub-id-type="pmid">27088908</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schubbert</surname> <given-names>S</given-names></name><name><surname>Cardenas</surname> <given-names>A</given-names></name><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Garcia</surname> <given-names>C</given-names></name><name><surname>Guo</surname> <given-names>W</given-names></name><name><surname>Bradner</surname> <given-names>J</given-names></name><name><surname>Wu</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Targeting the MYC and PI3K pathways eliminates leukemia-initiating cells in T-cell acute lymphoblastic leukemia</article-title><source>Cancer Research</source><volume>74</volume><fpage>7048</fpage><lpage>7059</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-1470</pub-id><pub-id pub-id-type="pmid">25287161</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seki</surname> <given-names>M</given-names></name><name><surname>Kimura</surname> <given-names>S</given-names></name><name><surname>Isobe</surname> <given-names>T</given-names></name><name><surname>Yoshida</surname> <given-names>K</given-names></name><name><surname>Ueno</surname> <given-names>H</given-names></name><name><surname>Nakajima-Takagi</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Lin</surname> <given-names>L</given-names></name><name><surname>Kon</surname> <given-names>A</given-names></name><name><surname>Suzuki</surname> <given-names>H</given-names></name><name><surname>Shiozawa</surname> <given-names>Y</given-names></name><name><surname>Kataoka</surname> <given-names>K</given-names></name><name><surname>Fujii</surname> <given-names>Y</given-names></name><name><surname>Shiraishi</surname> <given-names>Y</given-names></name><name><surname>Chiba</surname> <given-names>K</given-names></name><name><surname>Tanaka</surname> <given-names>H</given-names></name><name><surname>Shimamura</surname> <given-names>T</given-names></name><name><surname>Masuda</surname> <given-names>K</given-names></name><name><surname>Kawamoto</surname> <given-names>H</given-names></name><name><surname>Ohki</surname> <given-names>K</given-names></name><name><surname>Kato</surname> <given-names>M</given-names></name><name><surname>Arakawa</surname> <given-names>Y</given-names></name><name><surname>Koh</surname> <given-names>K</given-names></name><name><surname>Hanada</surname> <given-names>R</given-names></name><name><surname>Moritake</surname> <given-names>H</given-names></name><name><surname>Akiyama</surname> <given-names>M</given-names></name><name><surname>Kobayashi</surname> <given-names>R</given-names></name><name><surname>Deguchi</surname> <given-names>T</given-names></name><name><surname>Hashii</surname> <given-names>Y</given-names></name><name><surname>Imamura</surname> <given-names>T</given-names></name><name><surname>Sato</surname> <given-names>A</given-names></name><name><surname>Kiyokawa</surname> <given-names>N</given-names></name><name><surname>Oka</surname> <given-names>A</given-names></name><name><surname>Hayashi</surname> <given-names>Y</given-names></name><name><surname>Takagi</surname> <given-names>M</given-names></name><name><surname>Manabe</surname> <given-names>A</given-names></name><name><surname>Ohara</surname> <given-names>A</given-names></name><name><surname>Horibe</surname> <given-names>K</given-names></name><name><surname>Sanada</surname> <given-names>M</given-names></name><name><surname>Iwama</surname> <given-names>A</given-names></name><name><surname>Mano</surname> <given-names>H</given-names></name><name><surname>Miyano</surname> <given-names>S</given-names></name><name><surname>Ogawa</surname> <given-names>S</given-names></name><name><surname>Takita</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia</article-title><source>Nature Genetics</source><volume>49</volume><fpage>1274</fpage><lpage>1281</lpage><pub-id pub-id-type="doi">10.1038/ng.3900</pub-id><pub-id pub-id-type="pmid">28671687</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>J</given-names></name><name><surname>Whyte</surname> <given-names>WA</given-names></name><name><surname>Zepeda-Mendoza</surname> <given-names>CJ</given-names></name><name><surname>Milazzo</surname> <given-names>JP</given-names></name><name><surname>Shen</surname> <given-names>C</given-names></name><name><surname>Roe</surname> <given-names>JS</given-names></name><name><surname>Minder</surname> <given-names>JL</given-names></name><name><surname>Mercan</surname> <given-names>F</given-names></name><name><surname>Wang</surname> <given-names>E</given-names></name><name><surname>Eckersley-Maslin</surname> <given-names>MA</given-names></name><name><surname>Campbell</surname> <given-names>AE</given-names></name><name><surname>Kawaoka</surname> <given-names>S</given-names></name><name><surname>Shareef</surname> <given-names>S</given-names></name><name><surname>Zhu</surname> <given-names>Z</given-names></name><name><surname>Kendall</surname> <given-names>J</given-names></name><name><surname>Muhar</surname> <given-names>M</given-names></name><name><surname>Haslinger</surname> <given-names>C</given-names></name><name><surname>Yu</surname> <given-names>M</given-names></name><name><surname>Roeder</surname> <given-names>RG</given-names></name><name><surname>Wigler</surname> <given-names>MH</given-names></name><name><surname>Blobel</surname> <given-names>GA</given-names></name><name><surname>Zuber</surname> <given-names>J</given-names></name><name><surname>Spector</surname> <given-names>DL</given-names></name><name><surname>Young</surname> <given-names>RA</given-names></name><name><surname>Vakoc</surname> <given-names>CR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation</article-title><source>Genes &amp; Development</source><volume>27</volume><fpage>2648</fpage><lpage>2662</lpage><pub-id pub-id-type="doi">10.1101/gad.232710.113</pub-id><pub-id pub-id-type="pmid">24285714</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smallwood</surname> <given-names>SA</given-names></name><name><surname>Kelsey</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Genome-wide analysis of DNA methylation in low cell numbers by reduced representation bisulfite sequencing</article-title><source>Methods in molecular biology</source><volume>925</volume><fpage>187</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1007/978-1-62703-011-3_12</pub-id><pub-id pub-id-type="pmid">22907498</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spain</surname> <given-names>LM</given-names></name><name><surname>Guerriero</surname> <given-names>A</given-names></name><name><surname>Kunjibettu</surname> <given-names>S</given-names></name><name><surname>Scott</surname> <given-names>EW</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>T cell development in PU.1-deficient mice</article-title><source>Journal of immunology</source><volume>163</volume><fpage>2681-7</fpage><pub-id pub-id-type="pmid">10453009</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steidl</surname> <given-names>U</given-names></name><name><surname>Rosenbauer</surname> <given-names>F</given-names></name><name><surname>Verhaak</surname> <given-names>RG</given-names></name><name><surname>Gu</surname> <given-names>X</given-names></name><name><surname>Ebralidze</surname> <given-names>A</given-names></name><name><surname>Otu</surname> <given-names>HH</given-names></name><name><surname>Klippel</surname> <given-names>S</given-names></name><name><surname>Steidl</surname> <given-names>C</given-names></name><name><surname>Bruns</surname> <given-names>I</given-names></name><name><surname>Costa</surname> <given-names>DB</given-names></name><name><surname>Wagner</surname> <given-names>K</given-names></name><name><surname>Aivado</surname> <given-names>M</given-names></name><name><surname>Kobbe</surname> <given-names>G</given-names></name><name><surname>Valk</surname> <given-names>PJ</given-names></name><name><surname>Passegué</surname> <given-names>E</given-names></name><name><surname>Libermann</surname> <given-names>TA</given-names></name><name><surname>Delwel</surname> <given-names>R</given-names></name><name><surname>Tenen</surname> <given-names>DG</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells</article-title><source>Nature Genetics</source><volume>38</volume><fpage>1269</fpage><lpage>1277</lpage><pub-id pub-id-type="doi">10.1038/ng1898</pub-id><pub-id pub-id-type="pmid">17041602</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephens</surname> <given-names>DC</given-names></name><name><surname>Kim</surname> <given-names>HM</given-names></name><name><surname>Kumar</surname> <given-names>A</given-names></name><name><surname>Farahat</surname> <given-names>AA</given-names></name><name><surname>Boykin</surname> <given-names>DW</given-names></name><name><surname>Poon</surname> <given-names>GM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Pharmacologic efficacy of PU.1 inhibition by heterocyclic dications: a mechanistic analysis</article-title><source>Nucleic Acids Research</source><volume>44</volume><fpage>4005</fpage><lpage>4013</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw229</pub-id><pub-id pub-id-type="pmid">27079976</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramaniam</surname> <given-names>PS</given-names></name><name><surname>Whye</surname> <given-names>DW</given-names></name><name><surname>Efimenko</surname> <given-names>E</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Tosello</surname> <given-names>V</given-names></name><name><surname>De Keersmaecker</surname> <given-names>K</given-names></name><name><surname>Kashishian</surname> <given-names>A</given-names></name><name><surname>Thompson</surname> <given-names>MA</given-names></name><name><surname>Castillo</surname> <given-names>M</given-names></name><name><surname>Cordon-Cardo</surname> <given-names>C</given-names></name><name><surname>Davé</surname> <given-names>UP</given-names></name><name><surname>Ferrando</surname> <given-names>A</given-names></name><name><surname>Lannutti</surname> <given-names>BJ</given-names></name><name><surname>Diacovo</surname> <given-names>TG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Targeting nonclassical oncogenes for therapy in T-ALL</article-title><source>Cancer Cell</source><volume>21</volume><fpage>459</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2012.02.029</pub-id><pub-id pub-id-type="pmid">22516257</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname> <given-names>A</given-names></name><name><surname>Tamayo</surname> <given-names>P</given-names></name><name><surname>Mootha</surname> <given-names>VK</given-names></name><name><surname>Mukherjee</surname> <given-names>S</given-names></name><name><surname>Ebert</surname> <given-names>BL</given-names></name><name><surname>Gillette</surname> <given-names>MA</given-names></name><name><surname>Paulovich</surname> <given-names>A</given-names></name><name><surname>Pomeroy</surname> <given-names>SL</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Mesirov</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tatetsu</surname> <given-names>H</given-names></name><name><surname>Ueno</surname> <given-names>S</given-names></name><name><surname>Hata</surname> <given-names>H</given-names></name><name><surname>Yamada</surname> <given-names>Y</given-names></name><name><surname>Takeya</surname> <given-names>M</given-names></name><name><surname>Mitsuya</surname> <given-names>H</given-names></name><name><surname>Tenen</surname> <given-names>DG</given-names></name><name><surname>Okuno</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth</article-title><source>Cancer Research</source><volume>67</volume><fpage>5328</fpage><lpage>5336</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-4265</pub-id><pub-id pub-id-type="pmid">17545613</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Topper</surname> <given-names>MJ</given-names></name><name><surname>Vaz</surname> <given-names>M</given-names></name><name><surname>Chiappinelli</surname> <given-names>KB</given-names></name><name><surname>DeStefano Shields</surname> <given-names>CE</given-names></name><name><surname>Niknafs</surname> <given-names>N</given-names></name><name><surname>Yen</surname> <given-names>RC</given-names></name><name><surname>Wenzel</surname> <given-names>A</given-names></name><name><surname>Hicks</surname> <given-names>J</given-names></name><name><surname>Ballew</surname> <given-names>M</given-names></name><name><surname>Stone</surname> <given-names>M</given-names></name><name><surname>Tran</surname> <given-names>PT</given-names></name><name><surname>Zahnow</surname> <given-names>CA</given-names></name><name><surname>Hellmann</surname> <given-names>MD</given-names></name><name><surname>Anagnostou</surname> <given-names>V</given-names></name><name><surname>Strissel</surname> <given-names>PL</given-names></name><name><surname>Strick</surname> <given-names>R</given-names></name><name><surname>Velculescu</surname> <given-names>VE</given-names></name><name><surname>Baylin</surname> <given-names>SB</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer</article-title><source>Cell</source><volume>171</volume><fpage>1284</fpage><lpage>1300</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.10.022</pub-id><pub-id pub-id-type="pmid">29195073</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname> <given-names>LM</given-names></name><name><surname>Chang</surname> <given-names>CJ</given-names></name><name><surname>Plaisier</surname> <given-names>S</given-names></name><name><surname>Wu</surname> <given-names>S</given-names></name><name><surname>Dang</surname> <given-names>J</given-names></name><name><surname>Mischel</surname> <given-names>PS</given-names></name><name><surname>Liao</surname> <given-names>JC</given-names></name><name><surname>Graeber</surname> <given-names>TG</given-names></name><name><surname>Wu</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Determining PTEN functional status by network component deduced transcription factor activities</article-title><source>PLoS One</source><volume>7</volume><elocation-id>e31053</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0031053</pub-id><pub-id pub-id-type="pmid">22347425</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapnell</surname> <given-names>C</given-names></name><name><surname>Pachter</surname> <given-names>L</given-names></name><name><surname>Salzberg</surname> <given-names>SL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>TopHat: discovering splice junctions with RNA-Seq</article-title><source>Bioinformatics</source><volume>25</volume><fpage>1105</fpage><lpage>1111</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp120</pub-id><pub-id pub-id-type="pmid">19289445</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapnell</surname> <given-names>C</given-names></name><name><surname>Roberts</surname> <given-names>A</given-names></name><name><surname>Goff</surname> <given-names>L</given-names></name><name><surname>Pertea</surname> <given-names>G</given-names></name><name><surname>Kim</surname> <given-names>D</given-names></name><name><surname>Kelley</surname> <given-names>DR</given-names></name><name><surname>Pimentel</surname> <given-names>H</given-names></name><name><surname>Salzberg</surname> <given-names>SL</given-names></name><name><surname>Rinn</surname> <given-names>JL</given-names></name><name><surname>Pachter</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks</article-title><source>Nature Protocols</source><volume>7</volume><fpage>562</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1038/nprot.2012.016</pub-id><pub-id pub-id-type="pmid">22383036</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapnell</surname> <given-names>C</given-names></name><name><surname>Cacchiarelli</surname> <given-names>D</given-names></name><name><surname>Grimsby</surname> <given-names>J</given-names></name><name><surname>Pokharel</surname> <given-names>P</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Morse</surname> <given-names>M</given-names></name><name><surname>Lennon</surname> <given-names>NJ</given-names></name><name><surname>Livak</surname> <given-names>KJ</given-names></name><name><surname>Mikkelsen</surname> <given-names>TS</given-names></name><name><surname>Rinn</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells</article-title><source>Nature Biotechnology</source><volume>32</volume><fpage>381</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1038/nbt.2859</pub-id><pub-id pub-id-type="pmid">24658644</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turkistany</surname> <given-names>SA</given-names></name><name><surname>DeKoter</surname> <given-names>RP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The Transcription Factor PU.1 is a Critical Regulator of Cellular Communication in the Immune System</article-title><source>Archivum Immunologiae Et Therapiae Experimentalis</source><volume>59</volume><fpage>431</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1007/s00005-011-0147-9</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Vlierberghe</surname> <given-names>P</given-names></name><name><surname>Ambesi-Impiombato</surname> <given-names>A</given-names></name><name><surname>Perez-Garcia</surname> <given-names>A</given-names></name><name><surname>Haydu</surname> <given-names>JE</given-names></name><name><surname>Rigo</surname> <given-names>I</given-names></name><name><surname>Hadler</surname> <given-names>M</given-names></name><name><surname>Tosello</surname> <given-names>V</given-names></name><name><surname>Della Gatta</surname> <given-names>G</given-names></name><name><surname>Paietta</surname> <given-names>E</given-names></name><name><surname>Racevskis</surname> <given-names>J</given-names></name><name><surname>Wiernik</surname> <given-names>PH</given-names></name><name><surname>Luger</surname> <given-names>SM</given-names></name><name><surname>Rowe</surname> <given-names>JM</given-names></name><name><surname>Rue</surname> <given-names>M</given-names></name><name><surname>Ferrando</surname> <given-names>AA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>ETV6 mutations in early immature human T cell leukemias</article-title><source>The Journal of Experimental Medicine</source><volume>208</volume><fpage>2571</fpage><lpage>2579</lpage><pub-id pub-id-type="doi">10.1084/jem.20112239</pub-id><pub-id pub-id-type="pmid">22162831</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Visvader</surname> <given-names>JE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cells of origin in cancer</article-title><source>Nature</source><volume>469</volume><fpage>314</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1038/nature09781</pub-id><pub-id pub-id-type="pmid">21248838</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yashiro</surname> <given-names>T</given-names></name><name><surname>Kasakura</surname> <given-names>K</given-names></name><name><surname>Oda</surname> <given-names>Y</given-names></name><name><surname>Kitamura</surname> <given-names>N</given-names></name><name><surname>Inoue</surname> <given-names>A</given-names></name><name><surname>Nakamura</surname> <given-names>S</given-names></name><name><surname>Yokoyama</surname> <given-names>H</given-names></name><name><surname>Fukuyama</surname> <given-names>K</given-names></name><name><surname>Hara</surname> <given-names>M</given-names></name><name><surname>Ogawa</surname> <given-names>H</given-names></name><name><surname>Okumura</surname> <given-names>K</given-names></name><name><surname>Nishiyama</surname> <given-names>M</given-names></name><name><surname>Nishiyama</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The hematopoietic cell-specific transcription factor PU.1 is critical for expression of CD11c</article-title><source>International Immunology</source><volume>29</volume><fpage>87</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxx009</pub-id><pub-id pub-id-type="pmid">28338898</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>G</given-names></name><name><surname>Wang</surname> <given-names>LG</given-names></name><name><surname>Han</surname> <given-names>Y</given-names></name><name><surname>He</surname> <given-names>QY</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>clusterProfiler: an R package for comparing biological themes among gene clusters</article-title><source>OMICS: A Journal of Integrative Biology</source><volume>16</volume><fpage>284</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id><pub-id pub-id-type="pmid">22455463</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>B</given-names></name><name><surname>Horvath</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>A general framework for weighted gene co-expression network analysis</article-title><source>Statistical Applications in Genetics and Molecular Biology</source><volume>4</volume><pub-id pub-id-type="doi">10.2202/1544-6115.1128</pub-id><pub-id pub-id-type="pmid">16646834</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>JA</given-names></name><name><surname>Mortazavi</surname> <given-names>A</given-names></name><name><surname>Williams</surname> <given-names>BA</given-names></name><name><surname>Wold</surname> <given-names>BJ</given-names></name><name><surname>Rothenberg</surname> <given-names>EV</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Dynamic transformations of genome-wide epigenetic marking and transcriptional control establish T cell identity</article-title><source>Cell</source><volume>149</volume><fpage>467</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.01.056</pub-id><pub-id pub-id-type="pmid">22500808</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>C</given-names></name><name><surname>Sakuishi</surname> <given-names>K</given-names></name><name><surname>Xiao</surname> <given-names>S</given-names></name><name><surname>Sun</surname> <given-names>Z</given-names></name><name><surname>Zaghouani</surname> <given-names>S</given-names></name><name><surname>Gu</surname> <given-names>G</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Tan</surname> <given-names>DJ</given-names></name><name><surname>Wu</surname> <given-names>C</given-names></name><name><surname>Rangachari</surname> <given-names>M</given-names></name><name><surname>Pertel</surname> <given-names>T</given-names></name><name><surname>Jin</surname> <given-names>HT</given-names></name><name><surname>Ahmed</surname> <given-names>R</given-names></name><name><surname>Anderson</surname> <given-names>AC</given-names></name><name><surname>Kuchroo</surname> <given-names>VK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>6072</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms7072</pub-id><pub-id pub-id-type="pmid">25614966</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.38314.032</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Look</surname><given-names>A Thomas</given-names></name><role>Reviewing Editor</role><aff><institution>Harvard Medical School</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;T-ALL Leukemia Stem Cell &quot;stemness&quot; is Epigenetically Controlled by the Master Regulator PU.1&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Sean Morrison as the Senior Editor and Thomas Look as Reviewing Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>The manuscript by Wu and coworkers explores the mechanisms driving leukemia initiating cell activity in a mouse model of T cell lymphoblastic leukemia driven by loss of the <italic>Pten</italic> tumor suppressor gene in hematopoietic progenitors. This model characteristically acquires <italic>Myc</italic> activating chromosomal rearrangements during disease progression and leukemia growth becomes uncoupled with PI3K signaling. Early work had identified enrichment of leukemia initiating cell activity in Lin<sup>-</sup>CD3<sup>+</sup>Kit<sup>mid</sup>. Now transcriptomic analyses of this population compared to blasts identifies a transcriptional program enriched in surface markers and with prominent expression of TIM-3 and CD11c. Using these markers the authors can further enrich for the LIC compartment and refine the LIC-associated transcriptional signature. PU.1 emerges from these analyses as a potential master regulator of this transcriptional program and LIC activity directly linked with the regulation of TIM-3. A mechanistic link is proposed between PI3K signaling, β-catenin activation, PU.1 upregulation, TIM-3 expression as initiating cascade in leukemia development. Later on, a PI3K independent loop involving β-catenin, <italic>Pu.1</italic> and <italic>TIM-3</italic> maintains this program in LICs. PU.1 methylation in blast cells is shown as a potential mechanism for abrogating the activity of this program in blast cells. Therapeutically, inhibition of PU.1 with DB1976, an anti-TIM-3 antibody and rapamycin or BAY1082439 for debulking blast cells induces profound antileukemic effects.</p><p>This is an interesting, mature and clearly presented manuscript that dissects in great depth the mechanisms of LIC activity operating in mouse tumors generated by hematopoietic specific inactivation of <italic>Pten</italic>. Key strengths of the work as presented include the compelling phenotypes resulting from genetic inactivation of <italic>Pu.1</italic> in the <italic>Pten</italic> knockout mouse model and the profound antileukemic effects observed with inhibitors targeting the regulatory circuit implicated here in the maintenance of LIC activity.</p><p>While overall the findings are intriguing, the reviewers have suggestions to correct gaps in the experimental evidence provided. If the authors can address the issues noted below this could be a very interesting article.</p><p>1) Enthusiasm for the manuscript is limited by the lack of a compelling case for the relevance of the mechanisms proposed in human disease. KE-37 and CEM cell lines are analyzed as examples of PU.1<sup>+</sup> and PU.1<sup>-</sup> leukemia to illustrate the regulatory role of PU.1 on TIM-3 and CD11c, yet it is unclear that PU.1 expression or knockdown modifies the LIC activity in these lines or whether these lines really still have true LIC. Attention should be paid to the presence of MYC translocations and PTEN mutations in these lines. Correlative data on PU.1 TIM-3 and LMO2 in primary T-ALL samples is of interest but as the authors correctly and insightfully point out this correlation may reflect primarily developmental programs, which are potentially but not necessarily linked with LIC activity.</p><p>Evaluation of the LIC activity in primary human T-ALL xenografts (PDX models) following the TIM-3 CD11c markers and ideally testing the effects of PU.1 inhibition in human T-ALL LIC activity would greatly enhance the relevance and general interest of the results presented here. We ask this in the hope that the authors may already have data in human T-ALL models, because this type of data would take more than a few months to generate, which is a goal of <italic>eLife</italic>. If such data is not available, the authors should at least point out the need for such studies and acknowledge the limitations of established T-ALL cell lines for studying the biology of LSC populations.</p><p>2) In Figure 3D, the authors use PU.1-EGFP for PU.1 ChIP analysis. Was it not possible to do the ChIP-PU.1 experiment without introducing PU.1-EGFP? Isn't there an antibody suitable to detect PU.1 in ChIP-seq? The authors should do a straightforward ChIP-seq experiment for endogenous PU.1 and detect the genes that bind PU.1 in the TIM-3<sup>high</sup> mouse leukemia cell population. ChIP-PCR is subject to bias and it would be nice to show which of the 710 possible PU.1 target genes are actually bound by PU.1?</p><p>3) Figure 3H. Please include Western blot for TIM-3.</p><p>4) Figure 5C. β-catenin is also known to upregulate MYC and yet the TIM-3<sup>high</sup>PU.1<sup>high</sup> LSC T-ALL subpopulation appears to have low levels of MYC expression due to PU.1 activation. Could the authors include <italic>Myc</italic> expression levels in Figure 5C? Does the <italic>Myc</italic> expression level go up or down when β-catenin is becomes activated by TIM-3?</p><p>5) The authors propose a feed forward loop between PU.1/TIM-3 that is further regulated by active β-catenin, but the key data presented (Figure 5) are correlative and do not formally demonstrate that this is either a feed forward loop (i.e. that TIM-1 regulates PU.1 as well as the converse; nor that these are directly regulated by β-catenin). This needs to be strengthened or the concept of a feed forward loop should be downplayed in the interpretation.</p><p>Stylistic comments:</p><p>1) <italic>eLife</italic> does not limit the number of figures. Also each figure can have linked supplemental figures. In the current paper, each of the figures has too many panels, such that the panels are very small and the font size is much too small. These panels should be broken up, with an increased number of main figures and figure supplements so that the results are more accessible. Please label the graphs with bigger font size – it is hard to read the labels.</p><p>2) Figure 2E is a table in a figure, and lists a lot of sensitivity, resistance data etc. that are not described.</p><p>3) Overall the English in this paper is very understandable, but grammatical mistakes are found throughout the text. A scientific editor familiar with English grammar could very quickly improve the English grammar and clarity of the paper.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.38314.033</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p>Please note some of the gene names, such as PU.1, TIM-3, CD11c, have been changed to approved gene names systematically per editorial suggestions.</p><disp-quote content-type="editor-comment"><p>[…] While overall the findings are intriguing, the reviewers have suggestions to correct gaps in the experimental evidence provided. If the authors can address the issues noted below this could be a very interesting article.</p><p>1) Enthusiasm for the manuscript is limited by the lack of a compelling case for the relevance of the mechanisms proposed in human disease. KE-37 and CEM cell lines are analyzed as examples of PU.1<sup>+</sup> and PU.1<sup>-</sup> leukemia to illustrate the regulatory role of PU.1 on TIM-3 and CD11c, yet it is unclear that PU.1 expression or knockdown modifies the LIC activity in these lines or whether these lines really still have true LIC. Attention should be paid to the presence of MYC translocations and PTEN mutations in these lines. Correlative data on PU.1 TIM-3 and LMO2 in primary T-ALL samples is of interest but as the authors correctly and insightfully point out this correlation may reflect primarily developmental programs, which are potentially but not necessarily linked with LIC activity.</p></disp-quote><p>We appreciate reviewers’ critical comments on the human T-ALL cell lines used in our study. As indicated in the table below, KE-37 is <italic>PTEN</italic> null, <italic>NOTCH1</italic>WT and carries <italic>TRAD-MYC</italic> translocation, very similar to the genetic alterations associated with the <italic>Pten</italic> null T-ALL model used in our study, while CEM is <italic>PTEN</italic> null, <italic>NOTCH</italic> mutated and WT for <italic>c-MYC</italic> (Milani et al., 2018; Schubbert et al., 2014). We used these two lines to validate (1) the transcription regulation of the SPI1 target genes in human T-ALL (revised Figure 4I); and (2) the epigenetic regulation of the human <italic>SPI1</italic> expression (revised Figure 10). Our recent analysis also indicates that the expression levels of SPI1 and HAVCR2 are higher in human ETP T-ALL as compared to non-ETP T-ALL (<xref ref-type="fig" rid="respfig1">Author response image 1A</xref>). We concur that cell lines are most suitable for studying signaling and regulatory mechanism but not LIC activity.</p><p>Author response table 1.</p><p><table-wrap id="inlinetable2" position="anchor"><table frame="hsides" rules="groups"><tbody><tr><td valign="top"/><td valign="top">PTEN</td><td valign="top">NOTCH1</td><td valign="top">Myc</td></tr><tr><td valign="top"><italic>Pten</italic> null T-ALL</td><td valign="top">Null</td><td valign="top">WT</td><td valign="top"><italic>Tcra/b-Myc</italic></td></tr><tr><td valign="top">KE-37</td><td valign="top">Null</td><td valign="top">WT</td><td valign="top"><italic>TRAD-MYC</italic></td></tr><tr><td valign="top">CEM</td><td valign="top">Null</td><td valign="top">Mut</td><td valign="top">WT</td></tr></tbody></table></table-wrap></p><disp-quote content-type="editor-comment"><p>Evaluation of the LIC activity in primary human T-ALL xenografts (PDX models) following the TIM-3 CD11c markers and ideally testing the effects of PU.1 inhibition in human T-ALL LIC activity would greatly enhance the relevance and general interest of the results presented here. We ask this in the hope that the authors may already have data in human T-ALL models, because this type of data would take more than a few months to generate, which is a goal of eLife. If such data is not available, the authors should at least point out the need for such studies and acknowledge the limitations of established T-ALL cell lines for studying the biology of LSC populations.</p></disp-quote><p>We totally agree with reviewer’s comment and have indeed generated six T-ALL PDX models. Unfortunately, none of PDXs growing up in the NSG mice so far belong to ETP T-ALL subtype, which our model closely mimics to (revised Figures 7 and 8). We have now collected more bone marrow samples and transplanted equal number of ETP and non-ETP T-ALL cells into NSG mice. Our preliminary study reveals that non-ETP cells may have better reconstitution ability than ETP T-ALL cells in NSG mice (<xref ref-type="fig" rid="respfig1">Author response image <underline>1B</underline></xref>). Since ETP T-ALL is originated from early marrow or thymic progenitor cells before T cell commitment and its development depends on the functional thymic environment, NSG mice may not be suitable for studying human ETP T-ALL LICs without certain supplements or pre-requisitions, such as PTEN loss, which enables T cell differentiation in the absence of the recombination-activating gene (Reg) and substitutes for both IL-7 and pre-TCR signals (Guo et al., 2011; Hagenbeek et al., 2004).</p><fig id="respfig1"><object-id pub-id-type="doi">10.7554/eLife.38314.026</object-id><label>Author response image 1.</label><caption><title>ETP and non-ETP T-ALL have different HAVCR2 and SPI1 expression levels and leukemia reconstitution abilities.</title><p>(<bold>A</bold>). The HAVCR2 and SPI1 expression levels are significant higher in ETP T-ALL samples as compared to non-ETP T-ALL samples. ***, p&lt;0.001. (<bold>B</bold>). Bone marrow cells (1X10<sup>6</sup>) from human T-ALL patients were <italic>i.v.</italic> injected into the NSG mice. Leukemia reconstitution was determined when &gt;25% of the cells in the peripheral blood were human CD45+;CD7+ leukemic cells.</p></caption><graphic mime-subtype="jpeg" mimetype="image" xlink:href="elife-38314-resp-fig1-v2"/></fig><p>There are very few publications on T-ALL LIC and T-ALL PDX models. The majority of these published works are based on non-ETP subtype and their conclusions about LIC are not consistent with each other (Chiu et al., 2010; Cox et al., 2007). We are conducting more detailed LIC-enrichment studies as well as genomic analyses of all T-ALL samples we have in hand. In the meantime, we are also exploring <italic>in vitro</italic> culture systems.</p><p>Since these works will take more than several months to accomplish, we have revised our manuscript and acknowledged the limitations of established human T-ALL cell lines for studying the biology of LICs (Subsection “LSCs loses their “stemness” when <italic>Spi1</italic> expression is silenced by DNA methylation”, second paragraph and Discussion, last paragraph).</p><disp-quote content-type="editor-comment"><p>2) In Figure 3D, the authors use PU.1-EGFP for PU.1 ChIP analysis. Was it not possible to do the ChIP-PU.1 experiment without introducing PU.1-EGFP? Isn't there an antibody suitable to detect PU.1 in ChIP-seq? The authors should do a straightforward ChIP-seq experiment for endogenous PU.1 and detect the genes that bind PU.1 in the TIM-3<sup>high</sup> mouse leukemia cell population. ChIP-PCR is subject to bias and it would be nice to show which of the 710 possible PU.1 target genes are actually bound by PU.1?</p></disp-quote><p>The frequency of HAVCR2<sup>high</sup> subpopulation is about 1/10000 while regular ChIP-seq requires 10<sup>6-7</sup> cells. Since we can only sort about 4000 cells/hour, it is technically difficult to do the ChIP-seq analysis on endogenously isolated HAVCR2<sup>high</sup> subpopulation. Our attempts of expanding HAVCR2<sup>high</sup> subpopulation <italic>in vitro</italic> without changing its LSC activity have not been successful.</p><p>We also like to clarify the path that leads to the discovery of SPI1 in our study, which was not clearly described in our initial submission. We first used network component analysis, in which the activity of transcription factors can be deduced based on the expression levels of their target genes. Among the predicted transcription factors that may control the expression of HAVCR2<sup>high</sup> LSC signature genes, SPI1 scores the highest. We then compared 1079 HAVCR2<sup>high</sup> LSC-signature genes to 7180 T cell development related SPI1 target genes determined by the endogenous SPI1 ChIP-seq analysis (Zhang et al., 2012) and found 710 overlapping genes (please see revised description in the first paragraph of the subsection “SPI1 is the master regulator of LSC signature genes”).</p><disp-quote content-type="editor-comment"><p>3) Figure 3H. Please include Western blot for TIM-3.</p></disp-quote><p>We have now included Western blot for HAVCR2 in our revised Figure 4H.</p><disp-quote content-type="editor-comment"><p>4) Figure 5C. β-catenin is also known to upregulate MYC and yet the TIM-3<sup>high</sup>PU.1<sup>high</sup> LSC T-ALL subpopulation appears to have low levels of MYC expression due to PU.1 activation. Could the authors include Myc expression levels in Figure 5C? Does the Myc expression level go up or down when β-catenin is becomes activated by TIM-3?</p></disp-quote><p>As shown in the revised Figure 8A (original Figure 5C), <italic>Myc</italic> expression is indeed downregulated upon β-catenin activation in this <italic>in vitro</italic> system. MYC protein levels are also negatively correlated with the levels of non-phosphorylated β-catenin and HAVCR2 <italic>in vivo</italic>(revised Figure 2B and Figure 8C).</p><disp-quote content-type="editor-comment"><p>5) The authors propose a feed forward loop between PU.1/TIM-3 that is further regulated by active β-catenin, but the key data presented (Figure 5) are correlative and do not formally demonstrate that this is either a feed forward loop (i.e. that TIM-1 regulates PU.1 as well as the converse; nor that these are directly regulated by β-catenin). This needs to be strengthened or the concept of a feed forward loop should be downplayed in the interpretation.</p></disp-quote><p>We now have additional data to support the role of HAVCR2 in SPI1 regulation:</p><p>1) Treating the <italic>Pten</italic> null T-ALL model with the anti-HAVCR2 antibody for 2 days is sufficient to reduce HAVCR2<sup>high</sup> subpopulation, accompanied by reduced non-phosphorylated β-catenin levels <italic>in vivo</italic>, similar to the effects of tankyrase/β-catenin inhibitor BAY6060 shown in revised Figure 8G and Figure 12A.</p><p>2) Gal-9 is a ligand of HAVCR2. Previous studies indicate that Gal-9 is critical for HAVCR2 signaling and human AML LSC self-renewal (Kikushige et al., 2015). We have genetically deleted <italic>Gal-9</italic> and found that Gal-9 loss prevents the <italic>Pten</italic> null T-ALL development and HAVCR2<sup>high</sup> LSC formation in vivo, an effect similar to that of <italic>Spi1</italic> deletion (<xref ref-type="fig" rid="respfig2">Author response image 2</xref>).</p><fig id="respfig2"><object-id pub-id-type="doi">10.7554/eLife.38314.027</object-id><label>Author response image 2.</label><caption><title>Gal-9 is essential for the <italic>Pten</italic> null T-ALL LSC formation and leukemia development.</title><p>(<bold>A</bold>). Deletion of the HAVCR2 ligand Gal-9 delays or prevents the <italic>Pten</italic> null T-ALL development <italic>in vivo</italic>. (<bold>B</bold>). HAVCR2<sup>high</sup> LSCs at ETP stage in the <italic>Pten</italic> null T-ALL are eliminated by <italic>SPI1</italic> or <italic>Gal-9</italic> deletion <italic>in vivo</italic>.</p></caption><graphic mime-subtype="jpeg" mimetype="image" xlink:href="elife-38314-resp-fig2-v2"/></fig><p>Nevertheless, we do agree with reviewer’s critical comment since β-catenin-SPI1-HAVCR2 forms an inter-dependent regulatory circuit and lacking anyone of them will influence LSC generation and self-renewal, as indicated by our <italic>Pten;Spi1</italic> and <italic>Pten;Gal-9</italic> knockouts and combination treatment experiments. In our revised Figure 13, we replaced feed forward arrows with a shaded triangle to more accurately present our take-home message. We also replaced “feedback loop” with “regulatory circuit” in our revised manuscript.</p><disp-quote content-type="editor-comment"><p>Stylistic comments:</p></disp-quote><p><italic>1)</italic> eLife <italic>does not limit the number of figures. Also each figure can have linked supplemental figures. In the current paper, each of the figures has too many panels, such that the panels are very small and the font size is much too small. These panels should be broken up, with an increased number of main figures and figure supplements so that the results are more accessible. Please label the graphs with bigger font size – it is hard to read the labels.</italic> </p><p>We have revised figures per your instruction and the revised manuscript now contains 13 figures, 1 table and 4 supplementary figures:</p><p>– Revised Figure 1 is the original Figure 1.</p><p>– Revised Figures 2-3 and Table 1 are from the original Figure 2.</p><p>– Revised Figures 4 – 5 are from the original Figure 3.</p><p>– Revised Figure 6 is the original Figure 4.</p><p>– Revised Figures 7-8 are from the original Figure 5 and supplementary Figure 4.</p><p>– Revised Figures 9–10 are from the original Figure 6 and supplementary Figure 5.</p><p>– Revised Figures 11–13 are from the original Figure 7 and supplementary Figure 6.</p><disp-quote content-type="editor-comment"><p>2) Figure 2E is a table in a figure, and lists a lot of sensitivity, resistance data etc. that are not described.</p></disp-quote><p>The original Figure 2E has been moved to Table 1 with a clear description.</p><disp-quote content-type="editor-comment"><p>3) Overall the English in this paper is very understandable, but grammatical mistakes are found throughout the text. A scientific editor familiar with English grammar could very quickly improve the English grammar and clarity of the paper.</p></disp-quote><p>Thanks for pointing out this deficiency. The revised manuscript has been edited by Nature Research Editing Service.</p><p>References:</p><p>Hagenbeek, T.J., Naspetti, M., Malergue, F., Garçon, F., Nunès, J.A., Cleutjens, K.B.J.M., Trapman, J., Krimpenfort, P., Spits, H. (2004) The Loss of PTEN Allows TCR αβ Lineage Thymocytes to Bypass IL-7 and Pre-TCR–mediated Signaling. J Exp Med. Oct 4; 200(7): 883–894, doi: 10.1084/jem.20040495</p></body></sub-article></article>